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ABSTRACT 
Gene-directed enzyme prodrug therapy is a form of cancer therapy in which 
delivery of a gene that encodes an enzyme is able to convert a prodrug, a 
pharmacologically inactive molecule, into a potent cytotoxin. Currently delivery of 
gene and prodrug is a two-step process. Here, we propose a one-step method 
using polymer nanocarriers to deliver prodrug, gene and cytotoxic drug 
simultaneously to malignant cells. Prodrugs acyclovir, ganciclovir and 5-
doxifluridine were used to directly to initiate ring-???????? ??????????????? ??? ?-
caprolactone, forming a hydrophobic prodrug-?????????????-caprolactone) which 
was further grafted with hydrophilic polymers (methoxy poly(ethylene glycol), 
chitosan or polyethylenemine) to form amphiphilic copolymers for micelle 
formation. Successful synthesis of copolymers and micelle formation was 
confirmed by standard analytical means. Conversion of prodrugs to their cytotoxic 
forms was analyzed by both two-step and one-step means i.e. by first delivering 
gene plasmid into cell line HT29 and then challenging the cells with the prodrug-
tagged micelle carriers and secondly by complexing gene plasmid onto micelle 
nanocarriers and delivery gene and prodrug simultaneously to parental HT29 
cells. Anticancer effectiveness of prodrug-tagged micelles was further enhanced 
by encapsulating chemotherapy drugs doxorubicin or SN-38. Viability of colon 
cancer cell line HT29 was significantly reduced. Furthermore, in an effort to 
develop a stealth and targeted carrier, CD47-streptaidin fusion protein was 
attached onto the micelle surface utilizing biotin-streptavidin affinity. CD47, a 
marker of self on the red blood cell surface, was used for its antiphagocytic 
efficacy micelles bound with CD47 showed antiphagocytic efficacy when exposed 
to J774A.1 macrophages. Since CD47 is not only an antiphagocytic ligand but 
also an integrin associated protein, it was used to target integrin ?v?3, which is 
overexpressed on tumor-activated neovascular endothelial cells. Results showed 
that CD47-tagged micelles had enhanced uptake when treated to PC3 cells 
which have high expression of ?v?3. The synthesized multifunctional polymeric 
XIV 
micelle carriers developed could offer a new platform for an innovative cancer 
therapy regime. 
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CHAPTER 1: INTRODUCTION1 
1.1. GENE-DIRECTED ENZYME PRODRUG THERAPY (GDEPT) 
Gene therapy, is the insertion of genetic material into an individual’s cell to treat 
a disease. The development of gene therapy began during the 1960’s to early 
1970’s. During this time, two discoveries were made which helped establish gene 
therapy as a therapeutic approach—an efficient method of gene transfer and 
cloned forms of specific genes. The first clinical gene therapy protocol was 
approved in 1989 and since then, more than 1800 clinical trials have been 
approved world-wide, more than 60% for treatment of cancer (Figure 1.1) [1, 2]. 
Suicide gene therapy or GDEPT, is a form of gene therapy in which genes 
are delivered to the targeted cells and expressed. These genes have the ability 
to convert inactive molecules (prodrugs) to a toxic species (Figure 1.2). Ideally, 
activation of a prodrug occurs by an enzyme that is either expressed in the tumor 
 
Figure 1.1. Graphical representation of the different indications addressed by gene 
therapy clinical trials. Adapted from The Journal of Gene Medicine, Wiley and Sons 
(http://www.abedia.com/wiley/index.html). 
64.10%9.10%
8.20%
7.80%
1.80%
1.60% 0.70%
1.80%
2.40%
2.60% Cancer diseases
Monogenic diseases
Infectious diseases
Cardiovascular diseases
Neurological diseases
Ocular diseases
Inflammatory diseases
Other diseases
Gene marking
Healthy volunteers
1The material contained in this chapter was previously published in Nanomedicine for 
Drug Delivery and Therapeutics Ch. 15, (2013) 438-469, and Therapeutic Delivery 4 
(2013) 825-839. 
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site in higher concentrations or unique to the tissue. Various combinations of 
enzyme and prodrug systems have been proposed for GDEPT, these include 
classical suicide gene/prodrug combinations such as cytosine deaminase/ 5-
fluorocytosine, cytochrome P450/ cyclophosphamide, thymidine phosphorylase/
5-doxifluridine, and the most well studied strategy herpes simplex virus thymidine 
kinase/ganciclovir [3, 4]. 
1.1.1. Prodrugs for thymidine kinase (TK) 
The most prominent and well-studied enzyme/prodrug GDEPT therapy is the use 
of herpes simplex virus thymidine kinase (HSV-TK) in conjunction with a variety 
of guanosine-based prodrugs i.e. ganciclovir (GCV), penciclovir, acyclovir (ACV), 
valacyclovir, (E)-5-(2-bromovinyl)-2’-deoxyuridine, and 2’-exo-methano-
carbathymidine [4]. Here, HSV-TK enzyme converts the prodrugs to their
monophosphate, other cellular kinases (such as cellular guanylate kinase and 
cellular phosphoglycerate kinase) then convert the monophosphorylated form of 
the prodrug to the toxic triphosphate. Cell death is caused by inhibition of DNA 
Figure 1.2. Gene Directed Enzyme Prodrug Therapy. Current two-step delivery of 
gene and prodrug for the treatment of cancer. First, the activation enzyme is 
delivered and expressed in the cell. Second, the prodrug is administered and 
activated to its cytotoxic form by the enzyme, leading to cell death.  
2
 
polymerase by the incorporation of dGTP into elongating DNA during cell division 
[5, 6]. However, prodrugs of HSV-TK are dependent upon the ‘bystander effect’ 
for enhanced infectivity. The bystander effect for HTV-TK system was first 
described in 1990 by Moolten and Wells [7]. These experiments showed that 
even if only 10% of cells were transfected with HTV-TK gene plasmid, treatment 
with GCV could lead to 100% cell death. Several mechanisms for the bystander 
effect have been proposed, including: apoptosis, and gap junctions [8, 9]. The 
most accepted mechanism of the bystander effect is that the transfer of toxic 
metabolic products happens through gap junction intercellular communication 
(GJIC) [8, 10-13]. Cells and tissues use gap junctions to pass information from 
one cell to the next through channels. These channels are formed from two 
oligometric integral membrane proteins called connexons. Connexons regulate 
intracellular transfer of metabolites as well as ions [14]. It should be noted that in 
studies where GJIC was inhibited, the bystander effect was still observed [12, 
15]. Therefore, it is commonly agreed that bystander cell death is due to multiple 
combinations of cellular mechanisms. 
1.1.2. Prodrugs for thymidine phosphorylase (TP) 
TP is an endogenous enzyme reported to occur to a greater extent in tumor cells 
than in normal tissue. Furthermore, TP is an angiogenic factor meaning the 
upregulation of TP in cells has the potential for enhanced tumor growth. 5-
deoxyfluoridine (5’DFUR) is an analog of deoxyuridine and a prodrug of 5-
fluorouracil (5-FU). 5’DFUR is converted to its active and toxic form, 5-FU, 
through cleavage by TP. TP expression in some breast, ovarian, colorectal and 
gastric cancers is upregulated and therefore direct use of 5’DFUR has been 
researched [16-18]. Similar to the HSV-TK system, TP/5’DFUR exhibits a strong 
bystander effect [17]. Here, it has been shown that the bystander effect for the 
TP/5’DFUR system does not to require cell-cell contact [19] significantly 
enhancing TP/5’DFUR as a suicide gene pair.     
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1.2. CURRENT POSITION OF GENE THERAPY 
Despite the current successes with gene therapy, there are genuine concerns 
regarding the safety of gene transfer in humans as well as technical issues in 
terms of quality and stability of transgene expression; most notably, is the use of 
viral vectors for delivery of genes into host cells. In 1999, gene therapy was 
delivered a blow when 18-year old Jesse Gelsinger took part in a gene therapy 
clinical trial at the University of Pennsylvania in Philadelphia. He was 
administered a high dose of adenovirus for treatment of ornithine-
transcarbamylase. His immune system responded immediately and four days 
later he died due to multiorgan failure [20]. Markedly, this was the first known 
case in which a death could be directly linked to the viral vector used for the 
treatment. Despite the setback from Gelsinger’s death, gene therapy is still a 
promising tool for cancer therapy. As such, several gene therapy products have 
made their way into the clinical setting outside of the United States. 
Since 2000, several gene therapy based products have been approved for 
clinical use including GendicineTM and OncorineTM which received approval in 
China in 2003 and 2005, respectively. GendicineTM, developed by SiBiono Gene 
Tech Co., is an adenoviral vector in which E1 gene is replaced with a human p53 
cDNA for treatment of head and neck squamous cell carcinoma [21, 22]. 
OncorineTM, developed by Sunway Biotech Co. Ltd, contains a deletion in the 
E1B 55k region which restricts virus binding to p53 protein and is approved for 
use in combination with chemotherapy [23]. In 2004, Ark Therapeutics Group plc, 
obtained a GMP Certification in the European Union for the manufacture of gene-
based medicine, Cerepro® [24]. Cerepro®, is an adenoviral vector which carriers 
the gene for HSV-TK and is intended for the treatment of malignant brain tumors 
through GDEPT. In 2008, Cerepro® became the first and so far the only 
andenoviral vector to complete a phase III clinical trial [25, 26]. Most recently, in 
October, 2012, the European Commission granted marketing authorization for 
Glybera® for treatment of severe lipoprotein lipase deficiency [27].  
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It should be noted that these gene therapy products still employ viral vectors 
for their delivery. As noted by the death of Jesse Gelsinger, viral vector delivery 
is notorious for causing immunogenicity and tumorigenicity. Therefore, the use of 
nonviral delivery methods can and are explored for cancer gene therapy.  
1.3. NONVIRAL DELIVERY METHODS 
Incorporation of chemotherapeutic agents into nanoparticle-based drug delivery 
systems such as, liposomes, polymeric nanoparticles, microcapsules and 
micelles have been studied extensively for the delivery of drugs to treat a wide 
range of cancers [28-31]. Due to the fact that nanoparticles can be prepared using 
a variety of polymers, biodegradable polymers have been studied extensively. 
Moreover, considerable research has been conducted in the preparation of a 
variety of biodegradable polymeric nanoparticles for drug delivery [29, 32-35]. For 
these reasons, polymeric nanocarriers are a choice delivery system for cancer 
gene therapy. 
In particular, polymeric micelles have shown promise for their use in cancer 
treatment. Polymeric micelles can be prepared using a variety of biodegradable 
and FDA approved polymers [36, 37], which can house hydrophobic drugs 
enhancing bioavailability [38]. In addition, polymeric micelles possess a small 
size (< 200 nm) which allow them to passively target tumor cells through the 
enhanced permeability and retention (EPR) effect [39]. Both in the laboratory and 
clinically polymeric micelles are proving effective for cancer treatment [40].  
Currently, six micellar systems have made their way into clinical trials. NK105, 
and Genexol-PM are miceller formulations used for the encapsulation of 
paclitaxel (PTX). PTX is known to be useful combating ovarian, breast and lung 
cancers [41, 42]. PTX however has very serious side effects such as neutropenia 
and peripheral sensory neuropathy. In addition, due to the mixture of Cremophor 
EL and ethanol used to solubilize PTX, 2-4% of patients report anaphylaxis and 
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other severe hypersensitive reactions [43]. NC6004 is a poly(ethylene glycol) 
(PEG) based polymeric micelle for the entrapment of cisplatin. Cisplatin (cis-
dichlorodiammineplatinum[II] or CDDP) is commonly used to treat epithelial 
malignancies of the lung, ovarian, bladder, testis, head and neck, esophagus, 
gastric, colon and pancreas. However, similar to PTX, CDDP causes several 
serious adverse side effects such as nephrotoxicity and neurotoxicity, which lead 
to discontinued treatment [44]. Despite the development of platinum analogues 
(e.g. carboplatin and oxaliplatin) [45] to overcome CDDP related disadvantages, 
CDDP has higher toxicity and is the standard treatment for cancer therapy [46, 
47]. NC6004 was developed to reduce side effects associated to CDDP and to 
improve efficacy of delivery to targeted sites. NK012 is a micelle carrier 
composed of PEG-b-poly(glutamic acid) (PGlu), SN-38 (a metabolite of irinotecan 
hydrochloride, CPT-11) was conjugated to PGlu by coupling agent 1,3-
diisoproylcarboiimide and catalyst N-dimethylamino-phridine, causing PGlu to 
become more hydrophobic leading to micelle formation [48]. Both SP1049C and 
NK911 are micelle carriers developed for the encapsulation of doxorubicin, 
another widely used anticancer agent. 
1.4. COMPOSITION, FORMATION AND CHARACTERIZATION OF 
POLYMERIC MICELLES 
Interest in using block copolymers for drug delivery has arisen mainly because of 
their self-associative characteristics. Block copolymers are macromolecules with 
two or more different polymer blocks arranged in a linear and/or radial 
arrangement. Synthesis of di- and triblock copolymers has been studied 
extensively [49]. Commonly, block and graft copolymers are synthesized by ring-
opening polymerization [50, 51] or free radical polymerization [52, 53]. Diblock 
copolymers have shell and core structures. The hydrophilic shell segment 
protects the drug from the aqueous environment and stabilizes the micelle, while 
the hydrophobic core encapsulates the non-water soluble drug. In some cases, 
the core can be made up of a water soluble polymer caused to be hydrophobic 
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by chemical conjugation to a hydrophobic drug [54], or by complexation of two 
oppositely charged polyions [55]. In addition to diblock copolymers, multiblock 
copolymers i.e. triblock and graft copolymers, have been described as potential 
drug carrier systems [56, 57]. Generally, when the hydrophilic segment is longer 
than the core block, spherical micelles are formed (Figure 1.3). In contrast, rods 
and lamellae form when the length of the core segment is longer than the corona 
chain [58]. Choosing an appropriate copolymer system is essential to achieve an 
ideal drug carrier and every polymer combination has its own unique advantages. 
1.4.1. Micelle formation 
The hydrophobic corona of micellar systems is commonly made up of polyesters, 
polyethers and poly(amino acid) derivatives. Commonly used poly (L-amino 
acids) include poly(L-aspartate) and poly(L-glutamate). For these polymers to 
self-assemble into amphiphilic micelles, they need to be electrostatically neutral 
or conjugated to hydrophobic moieties [59].  FDA approved polyesters used in 
copolymer synthesis include poly(lactic acid) [60]?? ??????-caprolactone) (PCL) 
 
Figure 1.3. Block-copolymer micelle. A block-copolymer micelle loaded with a 
hydrophobic chemotherapeutic agent and functionalized with a target-specific ligand. 
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[61, 62] and poly(glycolic acid) [63, 64]. A triblock copolymer of pharmaceutical 
interest belongs to the poloxamer family, Pluronics (BASF Corp)  is a copolymer 
composed of poly(ethylene glycol)-b-poly(propylene oxide)-b-poly(ethylene 
glycol) [65]. Engineering of block copolymers affects the temporal and distribution 
controls of the polymeric micelles. Controlled release of the drug (temporal 
control) and site-specific delivery (distribution control) can be optimized through 
the choice of core and shell polymers. 
Routinely, the hydrophilic shell segment is made up of polyethers such as 
poly(ethylene glycol) (PEG) [66, 67] and poly(ethylene oxide) (PEO) [68-70]. 
These polymers are inexpensive, have a low toxicity and serve as efficient steric 
protectors of various biologically active macromolecules [70, 71]. The hydrophilic 
shell dictates biodistribution of the micelles, and polymers such as poly(N-
isopropylacrylamide) [52, 53] and poly(L-lactic acid) [72] impart temperature or 
pH-sensitivity to the polymeric micelle carrier. Natural polymers such as chitosan 
[73, 74] and dextran [75, 76] have also been employed as hydrophilic shell 
polymers due to the nontoxic and antimicrobial effects they can impart on the 
carrier. A list of hydrophobic and hydrophilic polymers used in micellar formation 
are given in Table 1.1. 
Table 1.1. Polymers used in the synthesis of block-copolymer micelles for drug delivery 
Hydrophobic (Core Forming) Segment 
??????-caprolactone) PCL 
O
O
n  
Poly(L-aspartate) PAsp N
H
H
N
H
N
O
O
CH2COOH
COOH
x y
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 Poly(L-lactide), 
Poly(D,L-lactide) 
PLA, 
PDLLA 
O
O
CH3
n
 
Poly(glycolic acid) PGA O
O
n  
Poly(propylene oxide) PPO 
O
CH3
n
 
Poly(L-histidine) PHis 
H
N
N
N
H
O
n
 
Hydrophillic (Corona-forming) Segment 
Poly(ethylene glycol) PEG 
O
n  
Poly(ethylene oxide) PEO 
Chitosan  O
O
O
NH2
OH
HO
HO
OH
HO
NH2
n
 
Dextran  
O
O
OH
O
OH
O
OH
O
OH
OH
n
m  
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 Poly(N-isopropyl 
acrylamide) 
PNIPAM, 
NIPAM O N
H
n
?
?
 
 
1.4.2. Preparation of micelles 
There are various techniques used for the self-assembly of polymers into micellar 
structures. Selection of appropriate preparation technique is largely based on the 
solubility of copolymer and drug solution. These methods are direct dissolution 
method, evaporation method and nanoprecipitation/dialysis method (Figure 1.4).
 
Figure 1.4. Techniques used for the preparation of polymeric micelles. (A) Direct 
Dissolution method: drug and copolymer are dissolved in water. (B) Evaporation 
method: drug and polymer are dissolved in an organic solvent, solvent is removed 
and polymer + drug are re-suspended in an aqueous solvent. (C) Dialysis method: 
drug and polymer are dissolved in an organic solvent that is miscible with water, 
the solvent mixture is slowly added to the water and then the solvent is removed 
by solvent-evaporation method or dialysis. 
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  Direct dissolution involves dissolving the block copolymer along with the 
drug in an aqueous solvent [77]. In contrast, the evaporation method is used for 
drugs and copolymers with limited water solubility [78]. The most commonly used 
method for the preparation of micellar carriers is the dialysis method which 
requires two steps. First, the amphiphilic copolymer and drug are dissolved in an 
organic solvent (acetone, ethanol or methanol) both have an affinity toward [79]. 
Micelle formation then proceeds by a solvent-evaporation method [80]. There are 
various types of solvent-evaporation methods. If the copolymer mixture is slightly 
water-soluble, it can be dialyzed against water to slowly remove the organic 
phase and trigger micellization [81]. The oil-in-water emulsion process both drug 
and polymer are dissolved in a water-miscible organic solvent such as 
tetrahydrofuran [82] or acetone [83].  This solution is slowly added to water under 
vigorous stirring/sonication, rearranging the polymer to form micelles. Micelle 
preparation varies with copolymer composition. Vangeyte et al. demonstrated 
that the dialysis procedure alone did not offer adequate size control of PEG-b-
PCL micelles, where as stable assembles were formed by first dissolving the 
polymer in an organic solvent and then dialyzing against water [84]. 
1.4.3. Factors affecting drug loading and drug release from polymeric micelles 
Drug loading into the micelle cores is achieved through either chemical 
conjugation or physical entrapment. Drug loading efficiency is calculated using 
the Flory-Huggins equation [85]. The partition coefficient (Kv) is used to calculate 
the extent to which a drug selectively partitions into the micelle core. The 
partitioning behavior of drugs in the core controls the amount of drug that can be 
solublized in block copolymer micelle carriers. Drug loading efficiency is 
dependent on many factors including the size of both the core and corona-
forming blocks, specific interaction between the drug and core and the method of 
micelle preparation. A larger hydrophobic block leaves a bigger core structure 
and therefore increases the ability to entrap the drug [86]. Drug release from 
polymeric micelles is dependent on the type of encapsulation process used to 
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load the drug. For a chemically conjugated drug, bulk degradation or surface 
erosion of the polymer slowly releases the drug. Conversely, for a physically 
entrapped drug, diffusion is the main mechanism for drug release. It had been 
shown that drugs incorporated into micelles have superior properties compared 
to the free drug [87]. Micelles have also been shown to decrease toxicity of a drug 
compared to the free form [88]. More recently, prodrugs of doxifluridine (5’-DFUR) 
[89] and acyclovir [90] have been used directly in the ring-opening polymerization 
????-caprolactone. Our lab has studied the toxicity of 5’-DFUR converted to 5-
fluorouracil by endogenous thymidine phosphorylase in colorectal cancer cells. 
Due to the fact that the prodrug is directly attached to the polymer micelle, another 
chemotherapy drug 7-ethyl-10-hydroxy-camptothecin (SN-38) was encapsulated 
in the hydrophobic core of the polymeric drug micelle which drastically increased 
cell death [91]. 
1.5. TARGETING SCHEMES 
Development of a good drug delivery system relies heavily on the selection of 
appropriate design parameters such as physiochemical limitations of the drug 
and/or route of administration. The development of nanoparticles has evolved 
substantially over the last few decades and there are several key strategies in 
the design of nanoparticles for therapeutic applications [92]. Although there are 
quite a few modes of drug administration with their own biological barriers for 
drug carriers to overcome, systemic delivery remains the most desired mode 
(e.g., treating metastatic cancer where tumor nodules are spread widely around 
the body). 
Systemic delivery of drug carriers is categorized into two classes: enteral 
and parenteral routes. Administration of a drug carrier in the enteral route is 
characterized by absorption of the drug through the gastrointestinal tract and 
includes oral or rectal administration. In contrast, parenteral drug administration 
does not pass through the gastrointestinal tract but is administered directly into 
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the bloodstream. The success of therapeutic carriers is dependent upon the 
mode of administration and thereby influences synthesis of the carrier. For 
example, oral administration must address carrier stability in the gastrointestinal 
tract, whereas intravenous injection must overcome the mononuclear phagocyte 
system (MPS) if prolonged blood circulation is desired. Additionally, the carrier 
must be designed to specifically target the site for entry [93, 94].  While each 
route of delivery has its own pros and cons, intravascular injection due to its 
precise and almost immediate onset of action is widely employed for drug 
delivery. 
Polymeric micelles are required to exhibit a sufficient half-life in the blood 
compartment in which solid tumors are normally located outside of. The critical 
micelle concentration (CMC) is the concentration at which the single chain 
polymers (unimers) begin to associate to from micelles. Polymeric micelles have 
a low CMC (10-4-10-7 M). CMC is affected by various properties including size of 
core block length. An increase in hydrophobic core length corresponds with a 
decrease in the CMC [95]. A longer hydrophobic core is also correlated with 
increasing micellar stability [96], increasing in vivo performance. The low CMC of 
micelles is advantageous for drug delivery because the carrier will not dissociate 
instantly upon intravenous injection to patients. 
The size, shape and surface characteristics all play a role in the 
biodistribution of particles used for drug delivery. The effect of size and shape on 
a particle has been studied extensively [97, 98]. Moreover, it is known that non-
biocompatible nanoparticles are easily recognized by the MPS [99]. Ideal carriers 
should be between 10-200 nm to avoid removal by the MPS [98]. If however, the 
carrier is larger than 200 nm several strategies have been developed by 
researchers to prolong circulation times of particles. The first is to pre-inject decoy 
carriers followed by injection of carriers containing therapeutic agents [100]. As a 
result, phagocytes of the MPS are saturated with decoy carriers, allowing 
therapeutic carriers to escape and reach the desired sites. Secondly, alterations 
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to the carrier surface can reduce the rate of protein opsonization or avoid 
complement activation. 
1.5.1. Passive targeting 
Another key problem for micelle carriers—or any drug carrier is developing an 
effective delivery method to and inside tumor cells. Many tumors exhibit a unique 
vasculature which possesses hyperpermeability and impaired lymphatic 
clearance from the interstitial space. Studies have established a phenomenon in 
which long-circulating polymeric carriers can effectively accumulate inside of 
solid tumors. The passive accumulation of drugs into tumors is termed the 
enhanced permeability and retention (EPR) effect. The EPR effect was first 
reported by Matsumura and Maeda in 1986 [101], since then, research into the 
EPR effect has grown considerably [39, 102, 103]. Solid tumors, generally 
possess a defective vascular architecture, high vascular density and/or active 
angiogenesis which can cause enhanced vascular permeability, as a result, 
particles ranging from 10-500 nm in size are able to penetrate the endothelial 
lining of tumor blood vessels and accumulate inside the interstitial space of 
tumors [104]. It is known that extensive production of vascular mediators such as 
bradykinin , nitric oxide , vascular permeability factor/vascular endothelial growth 
factor, prostaglandin , collagenase  and peroxynitrite  increase hyperpermeability 
of tumor blood vessels and increase the EPR effect [39, 105-111]. For the EPR 
effect to be useful in drug delivery, carriers must be long-circulating so that a 
sufficient amount of drug can be released into the target cells. One way to 
increase blood circulation time is through PEGylation. 
PEGylation is the process by which PEG chains are attached to a 
molecule or carrier, and the stealth properties of PEG lent to them. Since 
PEGylation was first described, several conjugation strategies have been 
developed. The variety of modification procedures offered allows for the 
PEGylation of a wide variety of carriers and molecules [112]. PEGylated 
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dendrimers [113], liposomes [114, 115] and micelles [91, 116] have been 
developed as viable therapeutic agents for cancer therapy. Moreover, PEGylation 
of chemotherapy drugs [117, 118], protein molecules [119] or monoclonal 
antibodies [120], has been employed to increase circulation half-life time and 
reduce immunogenicity, without decreasing activity. Chemical conjugation of 
adenovirus vectors with PEG has also emerged as a viable strategy to improve 
the safety and efficiency of viral gene-delivery vectors [121]. Polymers based on 
N-(2-hydroxypropyl)methacrylamide have shown particular promise not only as 
drug carriers, but for surface coating of viruses or targeted drug carriers [122, 
123]. While PEGylation has improved the pharmacokinetic properties of the 
aforementioned systems, overcoming immune clearance and cell entry across 
the endothelial lining and into the tissue itself is still something which needs to be 
addressed [124]. Furthermore, PEG has several drawbacks such as 
hypersensitivity reactions, non-biodegradability, instability under stress and 
toxicity of side products [124]. These disadvantages have prompted interest into 
the investigation of alternatives to PEG. There have been several alternatives to 
PEG suggested which reduce opsonization of drug carriers and increase blood 
circulation time [125-127]. Once the cells have reached the tumor site, several 
mechanisms have been proposed for the delivery of the drugs into the cells [128-
130]. Figure 1.5 illustrates a few of the proposed passive targeting mechanisms.
15 
   
 
Figure 1.5. Mechanisms of drug delivery from micelle carriers. (A) Drug is release 
from micelle carrier and diffuses into the cell. (B) The micelle carrier disassembles 
in extracellular space and the drug is released and diffuses into the cell. (C) Drug-
loaded micelles are taken up into the cell by endocytosis. The internalized drug-
loaded micelle reaches the lysosome where the drug is released by either (D) 
degradation of polymeric micelles or (E) diffusion. 
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1.5.2. Active targeting 
While passive targeting is achieved by exploiting the EPR effect, active targeting 
aims to increase drug delivery efficiency by taking advantage of the specific 
biological interactions between the tumor cell and carrier. Through conjugation of 
a tissue or cell-specific ligand to the carrier system (Figure 1.6), active targeting 
has been shown to enhance in vitro cytotoxicity against target cells [131]. Ligands 
can target tumor cells in several ways, two of which are through the 
neovasculature of angiogenesis and targeting uncontrolled cell growth. Active 
targeting also makes use of stimuli sensitivity such as pH and temperature 
sensitivity to target increased accumulation of drug into the target tissue. 
Kabanov et al. was one of the first groups to apply active targeting on a micellar 
???????????????????????????????????????2-glycoprotein, which targets brain glial 
??????? ??? ????????? ????????? ??????????? ?????? ?????? ???????? ??????? ????? ?2-
glycoprotein micelles had increased delivery to the brain and decreased 
clearance to the lung when compared to non-ligand conjugated pluronic micelles 
[132, 133]. Even though many believe active targeting is key for increased 
biodistribution, recent reviews suggest that the benefit of active targeting lies not 
with in its ability to increase the number of carries to the tumor but with its ability 
to facilitate in vivo cellular uptake through passive targeting [134]. 
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Figure 1.6. Polymeric micelles for targeted drug delivery. Surface modification 
allows for site-specific delivery of the drug to the tumor cells through receptor-
mediated endocytosis. (A) Ligand-coupled micelle approaches cancer cells (B) 
and bind to the cell surface receptors. (C) The micelles are internalized through 
receptor-mediated endocytosis. (D) In early endosomes, the micelle and 
receptors undergo sorting where the receptor returns to the cell surface and (E) 
then micelles enter the late endosome which later fuses with the lysosome.   
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1.5.3. Receptor-mediated targeting 
Cell proliferation markers can be overexpressed on certain tumor cells making 
them a good target for cancer therapeutics. Folate, human epidermal and 
transferrin receptors are the most commonly used ligand targets for cancer 
therapy. These targets are overexpressed in a wide range of tumor cells and their 
biological functions as well as internalization pathways have been studied 
extensively [135-137]. Ligand-mediated targeting of anticancer drugs to 
overexpressed receptors is increasingly becoming an effective strategy for 
improving therapeutic effect of cancer drugs [138]. Targeting cell proliferation 
receptors exploits tumor’s reliance on continued stimulation by growth factors and 
can ensure elimination by stemming the growth of highly malignant tumors and 
metastatic cells. 
Folic acid is one of the most highly researched targets for cancer therapy 
due to the fact that it is an essential vitamin for biosynthesis of nucleotide bases 
and is largely consumed by proliferating cells. The receptor for folic acid is 
overexpressed on epithelial tumors of various organs such as the colon, lung, 
prostate, ovaries, breast and brain [139]. After intercellular transport of folate-
equipped micelles, the drug is released intracellularly due to the slightly acidic 
(pH 5-6) conditions of endosomes. Moreover, folate conjugates have been shown 
to escape cancer cells multidrug efflux pumps and remain in recycling 
endosomes or escape into the cytoplasm [139]. Folate ligands are nontoxic, 
inexpensive, have a high binding affinity (10-10 M), low immunogenicity, can easily 
be conjugated to various drug carrier systems and can be stored stably [140]. 
The human epidermal receptor (HER) family of receptor tyrosine kinases 
consists of four closely released receptors.  Of these receptor tyrosine kinases 
epidermal growth factor receptor (EGFR) and human epidermal receptor-2 (HER-
2) are known to mediate cell signaling pathways involved in growth and 
proliferation in response to the binding of a variety of growth factor ligands [137]. 
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EGFR is overexpressed in one-third of all solid tumors including breast [141], 
lung [142], colorectal [143], head and neck [144], esophageal [145], renal cell 
[146], and prostate cancers [147]. There are six known endogenous ligands for 
EGFR: EGF, transforming growth factor-?? ????-???? ?????????????? ??????????????
heparin-binding EFG (HB-EFG) and epiregulin [148]. The most commonly 
detected in humans and therefore best studied are TGF-?? ???? ????? ????
presence of EGFR is frequently associated with metastatic spread [149] however 
it has also demonstrated to have pro-angiogenic properties [150]. Targeting 
EGFR as an anticancer strategy was first proposed in the 1980’s [151], there are 
now 13 anti-EGFR agents undergoing clinical trials either as monotherapy or in 
combination with standard treatment [137]. Several EGFR inhibitors mainly 
Iressa and Erbitux have even made their way to clinical trials with limited success 
[137] and are now FDA-approved [152, 153]. Reilly’s group is now undergoing 
phase 1 clinical trials with radiophamaceutical 111In-DTPA-hEGF for treatment of 
EGFR-overexpressing breast cancer cells [154]. 
Transferrin (Tf) is an iron-binding blood plasma glycoprotein that binds to 
trasferrin receptors (TfR) which are over expressed in malignant cells due to an 
increased iron requirement. Tf binds to endogenous iron in plasma, once bound 
to TfR, it is endocytosed into acidic compartments and the bound iron dissociates. 
TfRs are overexpressed in certain body tissues such as liver, epidermis, intestinal 
epithelium, vascular endothelium of the bran capillary and certain blood cells in 
the bone marrow. Tf-TfR mediated drug delivery has been studied for the 
treatment of breast cancer, prostate cancer and myeloid leukemia [136, 155, 
156]. Use of Tf has been given specific attention with regards to brain cancer 
because it can facilitate the transcytosis of drug carriers across the blood brain 
barrier. Yue’s group has used active targeting with several targeting moieties 
[157, 158]. Recently, the Tf-TfR interaction was studied because of the small 
amount of Tf needed to conjugate on the micelle and its higher endocytosis 
efficiency. Their results showed that Tf conjugation significantly increased cellular 
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uptake of Tf-micelles in MCF-7 and SGC-7901 cell lines. In vivo studies also 
confirmed antitumor effectiveness [159]. 
Angiogenesis is the physiological process involving the growth of new 
blood vessels from pre-existing blood vessels. Most mammalian cells retain a 
blood vessel size of 100 to 200 μm, to surpass this size, new blood vessels must 
be formed [160]. It is known that for a tumor cell to grow beyond its critical size 
or metastasize to another organ, new blood vessels must be formed. Therefore, 
in 1971, it was proposed that one way to stop tumor growth could be to block 
angiogenesis [161]. It is widely accepted that tumor angiogenesis happens by the 
activation of the ‘angiogenic switch’. When pro-angiogenic molecules and anti-
angiogenic molecules are in balance the switch is off but when that balance is 
turned, the switch is turned on [162]. There are now more than 30 known 
activators and inhibitors of angiogenesis of these, vascular endothelial growth 
factor receptors (VEGFR),  integrins, matrix metalloproteinase receptors and 
vascular cell adhesion molecule-1 are the most common angiogenic targets 
studied by nanoscale drug delivery systems [140]. 
VEGFR is one of the most commonly studied tumor angiogenesis inducers 
studied. VEGF ligands bind to and active three different type III receptor tyrosine 
kinases: VEGFR-1, VEGFR-2 and VEGFR-3. VEGFR-2 expression is restricted 
to the vasculature and therefore has been studied as an inducer of tumor 
angiogenesis [163]?? ?????????? ?v?3 is an arginine-glycine-asparic acid (RGD) 
containing molecule that is responsible for anchoring cells to the extracellular 
matrix. Several studies have found that ?v?3 has a key role in endothelial cell 
survival and migration during angiogenesis [164, 165]. In a recent study, PEG-b-
poly(lysine) micelles were complexed with cyclic RGD peptide and targeted to 
integrin expressing HeLa cells. Uptake of the micelles was viewed by comparing 
fluorescently labeled, targeted and untargeted micelles in live-cell imaging 
experiments through fluorescence microscopy and flow cytometry. Their results 
showed that RGD ligand accelerated the internalization of micelles [166]. 
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1.6. ENGINEERING ANTIPHAGOCYTIC BIOMIMETIC DRUG CARRIERS 
While synthetic biomaterials for therapeutic delivery have been significantly 
advanced in terms of functionality and diversity, they still lack in the complexity 
of natural particulates. For example, red blood cells (RBCs) exhibit a complex 
biological functionality: they possess a small size, flexibility and chemical 
composition which allow them to complete complex tasks flawlessly in the human 
body without being recognized as foreign particles for up to 4 months [167]. 
Pathogens such as bacteria and viruses have developed immune escaping 
mechanisms which allow them to infect tissues with maximum efficacy [168]. 
Recently, researchers’ understanding of immune surveillance has been growing 
greatly [169-171] and several immune system components have been implicated 
in the identification and elimination of cancer cells [172, 173]. To this end, the 
remarkable properties cells in the body possess are being exploited for the 
delivery of therapeutic and/or diagnostic agents. Due to the increased 
understanding of circulating body cells as carriers, surface biochemistry of blood 
cells, and the immune escaping mechanisms pathogens and tumor cells employ, 
researchers are taking a lead from nature in the design of drug carriers. Aided by 
advances in nanotechnology and biology, researchers are able to design delivery 
vehicles which mimic natural cells. These novel biomimetic strategies have been 
proposed to camouflage drug carriers in order to bypass immune surveillance. 
These systems prolong the circulation time in bloodstream and lead to effective 
delivery of theranostic agents. 
1.6.1. Erythrocyte-inspired therapeutic delivery 
To develop a RBC carrier, a multitude of techniques have been established for 
the loading of therapeutic agents without changing RBC’s physiological survival 
properties [174]. Of the erythrocyte ghost preparation methods available, 
hypotonic treatment is the standard preparation which retains the physiochemical 
characteristics of erythrocyte membranes [175, 176]. RBCs are placed in a 
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hypotonic solution where osmotic pressure releases the intracellular contents 
within the RBC membrane. Meanwhile, the therapeutic agent of interest in the 
solution can then passively diffuse into RBCs and retain inside the cells via 
????????????????????????????????????????????????????????????????????????????????-
?????????????????-galactosidase for the treatment of Gaucher’s disease [177], 
several enzyme replacement therapeutics have been developed, some of which 
have entered long-term clinical trials [178-181]. Furthermore, erythrocyte ghosts 
have been harnessed for the delivery of oligonucleotides [182] and plasmid DNA 
[183]. RBC carriers have also been used to entrap small drug molecules [184], 
increasing biodistribution of the drug. Likewise, the encapsulation of multiple 
drugs have been studied [185]. Erythrocyte ghosts engineered to contain 
hemagglutinin fusion protein found on lipid membranes and for encapsulation of 
superparamagnetic nanoparticles and anti-cancer drug decitabine has been 
made for sustained and targeted delivery [186]. 
RBC membrane-derived liposomes, termed nano-erythrosomes, were first 
reported by Lejeune et al. [187]. Recently, Hu et al. used the plasma membrane 
of erythrocyte ghosts to cloak biodegradable polymeric nanoparticles via 
membrane extrusion and demonstrated extended blood circulation half-life time 
of RBC membrane-camouflaged polymeric nanoparticles [188]. Compared to 
PEG-coated nanoparticles, which had an elimination half-life of 15.8 hours, the 
RBC-membrane-coated nanoparticles had an elimination half-life of 39.6 hours 
nearly double that of the control. Another way in which researchers are taking 
advantage of the properties of RBCs is through the coupling of therapeutic agents 
onto the outer surface of RBCs by covalent conjugation [189]. Taking advantage 
of ligands on the RBC surface, such as the complement receptor 1, drugs can be 
conjugated and their circulation time increased. A “hitchhiking” strategy was 
employed to attach therapeutic polymeric nanoparticles on the surface of RBCs 
through physical means and showed a drastic improvement in blood circulation 
time [190]. 
23 
 
1.6.2. Carrier cells for therapeutic delivery 
Natural carrier cells such as cytokine-induced killer (CIK cells), T cells and 
mesenchymal stem cells (MSCs) have all been exploited for the delivery of 
various therapeutic agents and for the delivery of oncolytic viruses. An advantage 
of using these cells is for their tumor-homing or tumor targeting abilities. 
Moreover, addition of therapeutic agents into these cells does not affect the 
integrity of the natural particulates. CIK cells have demonstrated the ability to 
localize into leukemia tissue and become toxic to them [191]. CIK cells have 
shown effective in the treatment of several solid malignancies including those of 
the lungs and ovaries [192, 193]. Success of CIK treatment in vivo has led to 
clinical studies of the treatment for solid tumors with encouraging results [194].  
Similar to CIK cells, T-cell based immunotherapies have shown successful 
in tumor immunotherapy by increasing the numbers of endogenous NK and CD8+ 
T cells which are potent mediators of antitumor immunity [195, 196]. Recently, T 
cells co-transduced with prostate tumor antigens to target tumor cells were 
successfully used for tumor treatment by Kloss et al. [197]. In the study, T cells 
were rendered tumor specific and elicited complete tumor remission without 
sacrificing T cell reactivity. 
MSCs exhibit migratory properties which make them attractive candidates 
for targeted delivery of genes and viruses. Recent studies have shown that MSCs 
are not only able to migrate to and incorporate within the connective tissue of 
tumors, but actively seek out metastases far removed from the primary tumor site 
[198-200]. MSCs have been utilized as delivery vehicles of interleukins in order 
to improve the anticancer immune surveillance by activating cytotoxic 
lymphocytes and NK cells [201]. MSCs have also been used as delivery agents 
for gene-directed enzyme prodrug therapy. Several prodrug-enzyme activation 
schemes are available for killing tumor cells and are being evaluated in clinical 
trials [202]. The approach of using MSCs to deliver a gene to a prodrug was first 
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explored by Aboody et al. through delivery of cytosine deaminase (CD) which can 
be used for activation of prodrug 5-fluorocytosine to 5-fluorouracil [203]. Kosaka 
et al. evaluated the effect of MSC transfection with adenovirus carrying CD 
followed by treatment of 5-fluorosytosine in vivo [204]. Their results showed that 
delivery of MSCs transfected with CD resulted in significant prolongation of 
survival of rats with glioma cells. Fei et al. transfected MSCs with lentiviral vectors 
expressing CD with similar success in decreased tumor viability [205]. Other 
prodrug-gene combinations have been studied in conjunction with MSCs. Mori et 
al. transfected HSV-TK into MSCs then treated glioma cells with the MSCs/TK 
followed by treatment with ganciclovir [206]. Their results showed that significant 
cell death occurred in glioma cells treated with MSCs/TK compared to non-
transfected MSCs. The use of MSCs for GDEPT and as targeting vehicles is 
proving very promising for treatment of various cancer types. 
1.6.3. Pathogen-inspired therapeutic delivery 
As our understanding of the methods by which pathogens evade the immune 
system has grown, the ability to apply the immune evasion capabilities of 
pathogens to material design has been developed. One of the earliest attempts 
to exploit a naturally derived polysaccharide was through the coating of 
liposomes with linear dextran [207]. Bacterial dextran is produced by the 
fermentation of sucrose with Leuconostoc mesenteroides [208]. After ethanol 
precipitation from the culture medium, acid hydrolysis is used to reduce the 
overall molecular weight of dextran. Dextran with an average molecular weight of 
70 kD has been used as a plasma volume expander [209]. Dextran coating 
enhances the circulation time of drug molecules [210] and stability of micelle 
carriers [75]. Coating of poly(lactic acid) nanoparticles with dextran induced a 
diminished protein adsorption [211]. Dextran coating prolonged the blood 
circulation time of carriers made of poly(methyl methacrylate) polymer [212] and 
contrast agents [213]. Hyaluronan covalently attached to the surface of lipid 
nanoparticles has been demonstrated to endow the carriers with extended 
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circulation and active targeting towards hyaluronan receptor CD44, which is 
highly expressed on tumors [214]. 
Heparin is known to modulate the action of several systems including viral 
entry [215] and angiogenesis [216]. Heparin is a member of the 
glycosaminoglycan family of carbohydrates and found on the surface of cells and 
in the extracellular matrix [217]. It is known that heparin-like polysaccharides can 
be obtained from microorganisms such as Escherichia coli and resembles a type 
II glycosaminoglycuronan chain [218]. Due to its biological and pharmacological 
activities heparin has been used to surface-functionalized a variety of 
nanoparticles [219]. Heparin-coated poly(methyl methacrylate) nanoparticles 
exhibited a prolonged blood circulation time for 2 days, because host factor H 
can bind to heparin and inhibit complement activation [212]. Recently, a heparin-
mimicking polymer conjugate was synthesized by Nguyen et al. [220]. The 
synthesized heparin was far more stable under stress than the control without 
sacrificing the native activity of heparin. 
1.6.4. CD47 
In 2000, Oldenborg et al. reported that CD47 functioned as a “marker of self” on 
murine RBCs [221]. Murine RBCs deficient in CD47 were rapidly cleared from 
the bloodstream by macrophages compared to wild-type mice. Indeed, as a RBC 
ages, CD47 expression levels decrease (30% lower expression of CD47) on the 
oldest RBCs compared to the youngest RBCs, clearly supporting the role of 
CD47 in long-term circulation of RBCs in the bloodstream [222]. CD47 is widely 
expressed on a majority of normal tissues in humans and other mammals and 
leads to the phagocytosis of aged or damaged cells [223]. CD47 regulates 
???????????????? ???? ???????????????????????? ????????????????????????????????????
macrophages [224]????????????????????????????????????????????????????????????
activated and myosin accumulation at the phagocytic synapse is repressed, 
leading to inhibition of Fc?? ??? complement receptor mediated phagocytosis 
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[225].  If the inhibitory signals generated by CD47-?????? ???????????? ????
sufficient to counteract the phagocytic signals mediated through Fc?? ???? ????
complement receptors, ingestion of particles (e.g., RBCs or CD47-tagged drug 
carriers) is reduced or inhibited (Figure 1.7).
 Moghimi et al., suggested that CD47 could represent a viable solution in 
the design of macrophage-evading therapeutic carriers [218]. Hsu et al. first 
demonstrated the antiphagocytic effect of soluble CD47-streptavidin (CD47-SA: 
containing only the extracellular domain of CD47) fusion protein, expressed in 
BL21 bacteria and then purified by biotinylated agarose column, on macrophage 
cells [226]. In the study, it was shown that perfluorocarbon-based oxygen carriers 
 
Figure 1.7. The interaction of phagocyte receptors and an opsonized particle 
tagged with CD47 ligand. ???? ???????????? ??? ?????? ???? ????? ?????????? ???
antiphagocytic signal onto the particle and competes against the phagocytic signal 
triggered by Fc?-IgG binding. If the negative signal dominates in this tug of war, 
the particle gets the chance to avoid phagocytic internalization. 
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were able to avoid being engulfed by J774A.1 macrophage cells for up to 2 hours 
after cells were pretreated with soluble CD47-SA for 1 hour. 
 Tsai et al. employed mammalian CHO cells transfected with CD47-
encoding plasmid (containing only extracellular domain sequence of CD47) to 
produce and biotinylate extracellular domain of CD47 ligand [227]. Streptavidin-
coated polystyrene microbeads of 2.1 μm in diameter were tagged with 
biotinylated CD47 with a density comparable to that on RBCs and exhibited 
significant phagocytosis resistance with THP-1 macrophages. Recently, 
Rodriguez et al. has led to the development of a man-made “Self” peptide which 
can inhibit phagocytosis and enhance delivery of nanoparticles [228]. Through 
structure biology and computer simulation, a 21-amino acid “Self” peptide 
fragment (shortened from the 117-amino acid extracellular domain of CD47). This 
peptide was then put onto fluorescent polystyrene nanobeads of size 160 nm. 
Within half an hour, the beads tagged with the peptide showed 4 times as many 
beads still in circulation compared to the control beads. Additionally, delivery of 
paclitaxel to tumor bearing mice with the peptide-tagged polystyrene nanobeads 
showed similar tumor size reduction as delivery by the standard paclitaxel carrier 
(i.e., Cremophor) without similar toxic side effects. 
1.7. RATIONALE AND HYPOTHESIS 
Cancer is a leading cause of death worldwide and was the cause of 8.2 million 
deaths in 2012. It is expected that the number of cancer cases will rise from 14 
million in 2012 to 22 million within the next two decades [229]. Despite 
considerable advances in surgical and adjuvant therapies, many forms of cancer 
still show resistance to treatment. One way researchers are combating cancer is 
through gene therapy, which is the insertion of genetic material into an 
individual’s cell to treat a disease. One approach scientists are using gene 
therapy to treat cancer is through GDEPT. In such an approach, a prodrug, a 
pharmacologically inactive molecule that requires enzymatic and/or chemical 
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transformation to release a cytotoxic drug, is given to the patient. The prodrug 
contains the drug which will be used to destroy the targeted cancer cells. The 
gene for a foreign enzyme and the prodrug are administered in a two-step 
process. That is, first the foreign gene is introduced into the targeted cancer cells, 
expressed and released into the cytoplasm and then the prodrug is administered. 
The prodrug is activated by the gene-expressed exogenous enzyme and 
converted to its cytotoxic form. 
 My thesis examines the potential of multifunctional polymeric prodrug 
micelles for cancer gene therapy. I hypothesize that (i) prodrugs ACV, GCV or 
5’DFUR can be used as initiators directly in ring-??????????????????????? ??? ?-
caprolactone to form a hydrophobic prodrug-?????????????-caprolactone) (PCL), 
(ii) the prodrugs released from PCL by acid hydrolysis and/or intracellular 
esterase can be converted to their active and toxic forms, via overexpressed 
enzyme (either HSV-TK or TP) in cancer cells, (iii) through design and synthesis 
of polymeric drug/gene nanocarriers, the releasing profile of the prodrug-
activating enzyme system will be optimized to achieve maximum anticancer 
effectiveness in both the classical two-step and a proposed one-step approach, 
and (iv) CD47-streptavidin bound to the micelle surface can endow 
antiphagocytic and targeting properties to the micelle nanocarrier. 
1.8. SPECIFIC AIMS 
1.8.1. Specific aim 1: Optimization of polymeric prodrug nanocarriers 
The anticancer prodrugs ACV, GCV and 5’DFUR will be utilized as initiators in 
the ring-???????????????????????????-caprolactone to form hydrophobic prodrug-
tagged PCL, which will be grafted with hydrophilic polymers (methoxy 
poly(ethylene glycol), polyethyleneimine, or chitosan) to form amphiphilic 
copolymers for the preparation of stable micellar nanoparticles. The synthesized 
prodrug-containing amphiphilic copolymers will be characterized accordingly 
using analytical tools. Experiments including self-assembly morphology, particle 
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size and charge, and critical micelle concentration will be used to determine the 
optimal parameters for polymeric nanocarrier formation. I will examine the degree 
of the prodrug released from synthesized amphiphilic polymers by using 
hydrolysis and esterase. Toxicity of the micelles will be determined against HT29 
colorectal cancer cell lines. 
1.8.2. Specific aim 2: Efficacy of polymeric prodrug nanocarriers on cancer 
cell treatment 
Polymeric micelles with promising features will be employed for both two-step 
and one-step toxicity studies. HT29 colorectal cells have been chosen as the 
biological model for cytotoxic studies. Because HT29 cells have endogenous TP, 
micelles formed with 5’DFUR will be used to encapsulate DOX or SN-38. 5’DFUR 
and chemotherapy drugs loaded into my most desirable polymeric nanocarriers 
will both be slowly released within the malignant cells possibly extensively 
enhancing the effectiveness of anticancer therapy by synergistic or additive 
activity. Micelles formed from ACV or GCV will be studied by two-step toxicity by 
delivering HSV-TK gene plasmid to cells. The one-step approach will be achieved 
by synthesizing polymeric nanocarriers containing prodrug and gene encoded 
plasmids and culturing with cancer cells. To achieve maximal anticancer 
effectiveness of my one-step approach using multifunctional polymeric 
nanocarriers, the releasing profile of prodrug-activating enzyme will be modulated 
in line with the prodrug releasing window. 
1.8.3. Specific aim 3: Antiphagocytic and targeted micelle carriers 
CD47-streptavidin fusion protein can be easily attached to biotyinylated 
substrates utilizing the biotin-streptavidin affinity, revealing antiphagocytic 
function. Furthermore, since CD47 is an integrin associated protein, it has the 
potential to be employed to target integrin ?v?3, which is overexpressed on tumor-
activated neovascular endothelial cells and unexpressed on mature quiescent 
30 
 
ones lined in blood vessels. Because the affinity of biotin to streptavidin is so high 
and the micelle surface does not have other proteins, the crude protein can be 
used for CD47 functionalization on the micelle surface. Here, micelles will be 
biotinylated and then bound with CD47-streptavidin crude protein. The CD47 
coated micelle will then be treated to macrophages and the antiphagocytic effect 
studied. Moreover, PC3 cells, which over express ?v?3 integrin, will be treated 
with CD47 tagged micelles and the targeting ability followed. 
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CHAPTER 2: POLYMERIC MICELLES FOR ACYCLOVIR 
DRUG DELIVERY2 
2.1. ABSTRACT 
Polymeric prodrug micelles for delivery of acyclovir (ACV) were synthesized. 
First, ACV was used directly to initiate ring-???????? ??????????????? ??? ?-
caprolactone to form ACV-polycaprolactone (ACV-PCL). Through conjugation of 
hydrophobic ACV-PCL with hydrophilic methoxy poly(ethylene glycol) (MPEG) or 
chitosan, polymeric micelles for drug delivery were formed. 1H NMR, FTIR, and 
gel permeation chromatography were employed to show successful conjugation 
of MPEG or chitosan to hydrophobic ACV-PCL. Through dynamic light scattering, 
zeta potential analysis, transmission electron microscopy, and critical micelle 
concentration (CMC), the synthesized ACV-tagged polymeric micelles were 
characterized. It was found that the average size of the polymeric micelles was 
under 200 nm and the CMCs of ACV-PCL-MPEG and ACV-PCL-chitosan were 
2.0 mg L-1 and 6.6 mg L-1, respectively. The drug release kinetics of ACV was 
investigated and cytotoxicity assay demonstrates that ACV-tagged polymeric 
micelles were non-toxic. 
2.2. INTRODUCTION 
Due to the fact that nanoparticles can be prepared using a variety of polymers, 
biodegradable polymers have been extensively studied for the field of polymer 
therapeutics [1-3]. While there have been many biodegradable polymeric 
nanoparticles synthesized for drug delivery, polymeric micelles have numerous 
advantages over other proposed colloidal delivery systems [4-7]. Many studies 
have shown the promise micelles have for drug delivery because they can be 
tailored for prolonged blood circulation time, cellular selectivity, and for their 
2The material contained in this chapter was previously published in Macromolecular 
Research 20, (2012) 1-4, and Colloids and Surfaces B: Biointerfaces 122 (2014) 738-
45. 
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controlled release capabilities [8-10]. In addition, micelles can be specifically 
synthesized to increase a drug’s solubility and bioavailability [11-14]. 
Acyclovir (ACV) is a guanosine-based prodrug most commonly used for 
the treatment of infections caused by herpes simplex virus (HSV) type 1 and 2, 
varicella zoster virus and, to a lesser extent, cytomegalovirus and Epstein-Barr 
virus [15]. Moreover, prodrug ACV can be converted to its cytotoxic 
phosphorylated form by herpes simplex virus thymidine kinase (HSV-TK) gene 
for cancer therapy [16]. That is, if the HSV-TK gene is delivered to actively 
dividing cancer cells, and ACV is subsequently administered to the cells, the TK 
enzyme phosphorylates ACV, yielding toxic metabolites which cause death in 
prodrug treated HSV-TK expressing cells [17-19]. However, due to ACV’s poor 
water solubility and ensuing low bioavailability, alternative delivery approaches 
are required to increase the therapeutic potential of ACV. Several methods 
reported are to couple ACV to biocompatible hydrophilic polymers [20-22] or 
encapsulation into drug carriers [23-25]. Although these processes increase the 
bioavailability of ACV as well as offer a practical treatment for patients, they are 
labor-intensive and cost-ineffective. As a first step towards the formation of ACV-
tagged polymeric micelles, we developed a novel technique for direct synthesis 
of ACV-PCL through the ring-opening polyme?????????????-???????????????-CL). 
Polymeric micelles consist of an inner core made of a hydrophobic block 
copolymer and an outer corona made of the hydrophilic block of the copolymer. 
PCL, having been widely used as the core-forming hydrophobic segment of 
nanoparticles, was selected as the model polymer for this study. PCL is a semi-
crystalline, linear resorbable aliphatic polyester. It has been commonly used in 
drug delivery systems because it is biodegradable and biocompatible. [26-28] 
PCL is commonly synthesized by ring-???????????????????????????-CL using an 
alcohol as an initiator and stannous (II) octoate (Sn(Oct)2) as a catalyst [29, 30]. 
In addition to using alcohol as the initiator, methoxy-poly(ethylene oxide) and 
starch have been employed as macroinitiators to form amphiphilic polymers. [31, 
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32]. In this study, prodrug ACV possessing hydroxyl groups was used as the 
initiator to obtain prodrug-PCL. Then, a hydrophilic compound (MPEG or 
chitosan) was grafted on the hydrophobic prodrug-PCL to form the amphiphilic 
block copolymer which already has the drug attached started from the ring-
opening polymerization. These synthesized ACV-tagged amphiphilic polymers 
can self-assemble in aqueous medium to form polymeric prodrug micelles for use 
as nanocarriers in drug delivery. 
Individual conjugation of ACV-PCL to a wide array of biocompatible 
hydrophilic polymers to form polymeric micelles each has their own advantages 
for drug delivery. With this in mind, we choose to assess the successful 
conjugation of two model hydrophilic polymers, MPEG and chitosan, to 
hydrophobic ACV-PCL. Chitosan is a natural polysaccharide derived from 
deacetylation of chitin. Chitosan’s biocompatible and biodegradable features 
have attracted much attention in biomedical and pharmaceutical research [27, 
33]. Similarly, MPEG is a biocompatible hydrophilic polymer commonly used in 
polymeric micelle formation. MPEG is inexpensive, non-toxic and is widely used 
to covalently modify biological macromolecules and surfaces [10, 34, 35]. Hence, 
ACV-PCL-MPEG and ACV-PCL-chitosan copolymers were synthesized.  The 
chemical structure and physical properties of the copolymers were characterized 
and micelle formation investigated. The drug release profiles of ACV from 
polymeric prodrug micelles and the biocompatibility of polymeric prodrug micelles 
were investigated in this study. 
2.3. MATERIALS AND METHODS 
2.3.1. Materials 
ACV was purchased from TCI (Tokyo, Japan). N,N’-dicyclohexyl carbodiimide 
??????? ?-CL, pyrene, and succinic anhydride were purchased from Acros 
Organics (Geel, Belgium). Sn(Oct)2, CDCl3 with 1% tetramethylsilane (TMS), 
deuterated dimethyl sulfoxide (DMSO-d6), dimethyl sulfoxide (DMSO), 
tetrahydrofuran (THF), dichloromethane (DCM), methanol, 2-propanol, hexane, 
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toluene, methoxypolyethylene glycol amine (MPEG-NH2; MW = 5,000), and 
chitosan oligosaccharide lactate (MW = 5,000) were all purchased from Sigma-
Aldrich (St. Louis, MO). Ethyl ether was purchased from J.T. Baker (Austin, TX). 
N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar (Ward Hill, MA). 
Acetone was purchased from Pharmco-AAPER (Shelbyville, KY). Pyridine and 
hydrochloric acid (HCl) were purchased from EMD (Philadelphia, PA). Sodium 
chloride (NaCl) and magnesium sulfate were purchased from Showa (Tokyo, 
Japan). All reagents were used as received without further purification. 
2.3.2. Characterization methods 
Gel permeation chromatography (GPC) analyses were performed on a Waters 
1525 binary HPLC pump equipped with a Waters 2414 refractive index detector 
(Milford, MA). Waters styragel HR 3 (MW = 500 – 30,000) and HR 4E (MW = 50 
– 100,000) columns were equipped. Molecular weight calibration was performed 
with polystyrene standards that covered a MW range of 400 – 4.3 × 104. GPC 
analyses were performed in THF at a flow rate of 1 mL min-1 with an injected 
volume of 50 μl. 1H NMR spectra were obtained from a Varian Unity/Inova 400 
MHz instrument (Sparta, NJ). To obtain FTIR spectra by a Jasco FTIR-4200 
spectrometer (Tokyo, Japan), a small amount of polymeric sample was loaded 
onto a silicon wafer and THF was added dropwise to dissolve the sample and 
evaporated afterwards. This was repeated until the entire sample was dissolved 
and a film had formed. 
2.3.3. Synthesis of ACV-tagged amphiphilic polymers 
????????????????????????????????????????-CL (2.25 mL) under a sonication 
bath for 5 min at room temperature. Sn(Oct)2 ??????? ?????-CL) was then added 
into the mixture. The entire solution was placed into a 3-necked round-bottom 
flask. The system was purged with nitrogen and immersed in an oil bath at 140oC 
for 24 h. The crude product was cooled to room temperature, dissolved in DCM, 
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and precipitated by cold methanol. The product was then vacuum dried by a 
rotary evaporator at 40oC. 
ACV-PCL (0.5 mmol) and succinic anhydride (1 mmol) were weighed and 
dissolved in toluene in a 3-necked round-bottom flask. One mmol pyridine was 
added and the solution was reacted under nitrogen at 70oC for 48 h. The product 
was then precipitated by cold hexane, and spun down. The pellet was re-
dissolved in DCM and washed twice each with 10% (v/v) HCl and saturated NaCl 
solution. The organic phase was isolated and dried with magnesium sulfate then 
filtered. The carboxylated ACV-PCL was recovered by precipitation in cold 
hexane and then vacuum dried by rotary evaporation at 40oC. 
ACV-PCL-COOH (0.54 mmol) and NHS (2.7 mmol) were weighed and 
mixed in 15 mL DCM, and then DCC (2.7 mmol) was added. The reaction was 
run under a nitrogen environment at room temperature for 24 h. The precipitated 
byproduct 1,3-dicyclohexylurea was removed by vacuum filtration. The filtrate 
was added into 35 mL diethyl ether and cooled to 4oC for 4 h to precipitate ACV-
PCL-NHS. The precipitate was collected by centrifugation at 3,500 rpm for 5 min, 
washed with 2-propanol and solvent removed by rotary evaporation at 40oC. 
ACV-PCL-NHS (10 mg) and MPEG-NH2 (10 mg) were weighed and 
dissolved by 20 mL DCM in a round-bottom flask. The flask was purged with 
nitrogen and the solution was stirred for 24 h. The solution was then dialyzed 
(MWCO = 6-8 kD, Spectra/Por, Rancho Dominguez, CA) against pure DCM to 
remove remaining MPEG-NH2. ACV-PCL-MPEG was recovered by rotary 
evaporation at 40oC. 
ACV-PCL-NHS (10 mg) was dissolved in 5 mL acetone and slowly added 
to chitosan solution (20 mg chitosan oligosaccharide lactate dissolved in 25 mL 
deionized water). The mixture, purged with nitrogen, was stirred in a round-
bottom flask for 24 h. The reacted solution was vacuum dried to remove acetone 
and then lyophilized. The amphiphilic polymer was then dissolved in DCM and 
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dialyzed (MWCO = 6-8 kD, Spectra/Por) against pure DCM to remove unreacted 
chitosan. ACV-PCL-chitosan was recovered by rotary evaporation at 40oC. 
2.3.4. Preparation of polymeric prodrug micelles 
ACV-PCL-MPEG and ACV-PCL-chitosan micelles were formed similarly. Briefly, 
10 mg of ACV-tagged amphiphilic polymer was dissolved in 2 mL acetone. The 
solution was then added dropwise to 10 mL deionized water under sonication. 
Acetone was removed by rotary evaporation and the final solution was collected 
by filtering through a 0.45 μm filter. 
2.3.5. Determination of critical micelle concentration 
The CMC was estimated by using pyrene as a fluorescent probe [36]. Briefly, 1 
mg mL-1 of polymeric prodrug micelle was formed. Various amounts of deionized 
water and micellar solution were added respectively to glass vials to obtain 
micellar concentrations ranging from 5 × 10-7 to 1 mg mL-1. Pyrene in acetone 
was then added separately to the prepared vials to get a final concentration of 
pyrene in water of 6.0 × 10-7 mg mL-1, slightly lower than the saturation solubility 
of pyrene in water [37]. The solutions were then allowed to equilibrate for 8 h. 
Fluorescent spectra were determined by a plate reader (Synergy MX, BioTek, 
Winooski, VT) with an excitation wavelength of 334 nm. 
2.3.6. Size and morphology of polymeric prodrug micelles 
The average particle size of polymeric prodrug micelles was determined by a 
dynamic light scattering (DLS) instrument (Zetasizer Nano ZS, Malvern 
Instruments, United Kingdom) equipped with a red laser at a wavelength of 633 
nm and scattering angle of 90o at 25oC. The zeta potential of the micelles 
dispersed in deionized water was determined with a zeta potential analyzer 
(Zetasizer Nano ZS). Transmission electron microscopy (TEM) image of micelles 
was performed on a JEM-4000FX (JEOL, Tokyo, Japan) at 80 kV. The TEM 
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samples were prepared by adding 10 μL of micellar solution (1 mg mL-1) onto a 
Formvar grid for 5 min and wicking away solution in excess. The samples were 
negatively stained with 10 μL phosphotungstic acid solution (2 wt%) for 10 sec 
and then 15 sec, wicking away excess staining solution each time. 
2.3.7. Drug release kinetics 
Polymeric prodrug micelles at a concentration of 1 mg mL-1 were made in 
phosphate buffered saline (PBS) (1 M, pH 7.4) at 25oC.  Two mL of solution was 
placed in a dialysis tube (Float-A-Lyzer, Spectra/Por) with a MWCO of 3.5 – 5 
kD. The dialysis bag was then immersed in 50 mL PBS at room temperature. At 
specified time intervals, 5 μL of sample was removed and replaced with fresh 
PBS. The amount of ACV released was analyzed by a plate reader (BioTek) at 
254 nm. All experiments were carried out in triplicate. 
2.3.8. Cytotoxicity test 
24-well plates were seeded with human colorectal HT29 cells (HTB-38; ATCC, 
Manassas, VA) suspended in 0.5 mL Dulbecco’s modified Eagles’ medium 
(DMEM, Corning Cellgro, Manassas, VA) supplemented with 10% fetal bovine 
serum (FBS, Atlanta biologicals, Flowery Branch, GA) and 1% penicillin-
streptomycin (Sigma) and incubated at 37oC in 5% CO2 balanced with humidified 
air for 24 h. In each well, 500 μL of 1 mg mL-1 ACV-PCL-MPEG or ACV-PCL-
chitosan polymeric micelles (filtered by a 0.22 μm filter) was added. After 
incubation for 48 h, cell viability was assessed using MTT assay. 200 μL of sterile 
MTT solution (4 mg mL-1) was added into the culture wells and incubated for 4 h. 
The medium containing unreacted MTT was removed and 300 μL DMSO was 
added to dissolve the insoluble purple formazan crystals formed in cellular 
mitochondria. The absorbance at 590 nm was measured with a plate reader 
(BioTek) and results were recorded as viability percentage calculated against the 
control group without micellar challenge. All experiments were carried out in 
triplicate. 
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2.4. RESULTS AND DISCUSSION 
2.4.1. Synthesis and characterization of amphiphilic prodrug polymers 
ACV-PCL was synthesized through ring-???????????????????????????-CL, which 
was initiated exclusively by ACV (Figure 2.1 A). The 1H NMR spectra of 
guanosine-based prodrug ACV and ACV-PCL 24 h post-synthesis are shown in 
Figure 2.2 (i) and (ii), respectively. Judging from the ACV-PCL spectrum, 
chemical shifts at 3.75 (e, f-CH2), 5.44 (d-CH2), 7.68 (b-CH) were assigned to 
????????????????????????????????????????????-CH2), 1.64 (2-CH2), 2.29 (1-CH2) 
 
Figure 2.1. Synthetic scheme of (A) ACV-PCL, (B) ACV-PCL-COOH, (C) ACV-PCL-
NHS, (D) ACV-PCL-MPEG, and (E) ACV-PCL-chitosan. 
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and 4.04 (4-CH2) correspond with the backbone chain of PCL polymer. The 
characteristic resonances of PCL and ACV were both observed in the 
synthesized polymer. Although the characteristic peaks of ACV in Figure 2.2 (ii) 
are much lower than those representing PCL, the evidence of coupling of ACV’s 
protons in synthesized ACV-PCL is clear. 
 By 1H NMR spectra, the number average degree of polymerization was 
determined by taking the ratio of the integral values of the resonance peaks 
corresponding to the terminal methylene proton signal of PCL to the internal 
methylene proton signal of PCL according to the following equation: 
 Degree of Polymerization (Xn, NMR) =
'
'
4
44
I
II ?
   (1) 
Where 4I and '4I , are the peak areas for the internal methylene protons of PCL 
(4.04 ppm) and the terminal methylene protons of PCL (3.63 ppm), respectively. 
Figure 2.2. 1H NMR spectra of (i) ACV and (ii) ACV-PCL. 
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Table 2.1. Number-averaged molecular weight (Mn) and degree of polymerization (Xn) 
of ACV-PCL prepared by the ring-opening polymerization of ?-CL using ACV as the 
initiator and Sn(Oct)2 as the catalyst 
Time 
(min) 
Mna 
(Da) Xn GPC
a Xn NMRb 
1440 8812 75.2 55.3 
120 8356 71.2 50.3 
60  8020 68.3 44.0 
40 5819 49.0 42.7 
30 5834 49.1 24.6 
20 1388 10.2 19.8 
aCalculated by GPC, bCalculated by 1H NMR 
 Table 2.1 summarizes the results concerning the ring-opening 
polymerization of ACV-PCL.  It clearly indicates that polymers with high molecular 
weight were obtained given sufficient reaction time. The number-average 
molecular weight (Mn) obtained via GPC increases as the polymerization reaches 
completion. By 60 min, the polymerization was unimodal and there was little 
change in molecular weight (Mw) and Mn shows that the reaction is nearing 
completion. Degree of polymerization (Xn,GPC) was obtained by GPC according to 
the following equation: 
CL-
ACVn
GPCn, M
)MM(X
?
??       (2) 
There is some discrepancy between the Xn obtained from GPC and NMR data. 
This is because GPC data was calibrated relative to polystyrene standards. It is 
surmised that the deviation could be decreased if attempts are made to correct 
the GPC data by using the Mark-Houwink equation [30, 38]. 
ACV-PCL was further conjugated with either MPEG or chitosan as shown 
in Figure 2.1 B-E. Successful conjugation of MPEG or chitosan was confirmed by 
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GPC, 1H NMR and FTIR analyses. The increase in Mn of ACV-PCL to 22 kDa 
from 17.5 kDa corresponds with the addition of MPEG (Table 2.2). Figure 2.3 
shows the 1H NMR of MPEG-NH2 and ACV-PCL-MPEG. The peak at 3.63 (A-
OCH2) attributed to MPEG can be clearly seen in Figure 2.3 (iv). Due to the 
conjugation of MPEG to ACV-PCL though amide linkage (Scheme 2.1 D), the 
change of the peak at 1.79 (B-NH2) from a singlet in Figure 2.3 (iii) to a multiplet 
in Figure 2.3 (iv) further confirms conjugation of MPEG to ACV-PCL. Further 
characterization of successful grafting of MPEG to hydrophobic ACV-PCL was 
examined through FTIR analysis. FTIR spectra of ACV-PCL (A), MPEG-NH2 (B) 
and ACV-PCL-MPEG (C) are shown in Figure 2.4. C-H stretching vibrations can 
be seen from 2945-2852 cm-1 for all samples. The typical bending vibration of 
1634 cm-1 for the NH2 bending amide I band can be seen in ACV-PCL and ACV-
PCL-MPEG spectra, and is attributed to ACV. PCL and MPEG blocks were 
characterized by prominent absorptions at 1726 cm-1 (C=O) and 1112 cm-1 (C-
O-C), respectively. These peaks are found in ACV-PCL-MPEG copolymer 
ascertaining successful bonding of MPEG to ACV-PCL.  
Table 2.2. Characterization of ACV-PCL grafted with hydrophilic polymersa 
Sample Mw 
(Da) 
Mn 
(Da) 
Polydispersity 
(Mw/Mn) 
ACV-PCL (24 h) 28640 17491 1.64 
 ACV-PCL-MPEG 31746 22399 1.41 
ACV-PCL-chitosan  30916 21745 1.42 
aMeasured by GPC 
  GPC analysis revealed that the Mn of ACV-PCL increased from 17.5 kDa 
to 21.7 kDa after grafting with chitosan and had a PDI of 1.42 (Table 2.2). 
Successful conjugation of chitosan to ACV-PCL was characterized similar to 
ACV-PCL-MPEG. Figure 2.5 reveals the 1H NMR of chitosan (v) and ACV-PCL-
chitosan (vi). As shown in Scheme 2.1 E, conjugation of chitosan to ACV-PCL is 
made via amide linkage. The peak at 1.79 (A-NH2) from a singlet to a multiplet in 
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Figure 2.5 (vi) confirms conjugation of chitosan to ACV-PCL. Moreover, the peaks 
from the aromatic protons on C3 – C6 ??????????????????????????– 3.85, slightly 
shifted downward from the peaks shown in the original chitosan sample. 
 
Figure 2.3. 1H NMR spectra of (iii) MPEG and (iv) ACV-PCL-MPEG. 
57 
 
 
Figure 2.4. FTIR spectra of (A) ACV-PCL, (B) MPEG-NH2, and (C) ACV-PCL-MPEG. 
 
Figure 2.5. 1H NMR spectra of (v) chitosan and (vi) ACV-PCL-chitosan. 
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Figure 2.6 depicts the FTIR spectra of ACV-PCL (A), chitosan (B), and 
ACV-PCL-chitosan (C). OH stretching from 3429 – 3167 cm-1 as well as peaks at 
1634 cm-1 and 1521 cm-1 corresponding to the N-H bending vibrations of the 
amide I and II bands are attributed to ACV and chitosan, respectively. The 
aforementioned peaks as well as the carbonyl absorption at 1726 cm-1 associated 
with PCL and a peak at 1065 cm-1 (C-O-C) seen in each spectra are found in 
ACV-PCL-chitosan. The FTIR results are in line with the results from 1H NMR 
and demonstrate successful synthesis of ACV-PCL-chitosan.
2.4.2. Formation and characterization of ACV-tagged polymeric micelles 
Due to the amphiphilic nature of the synthesized ACV-PCL copolymers (i.e., 
ACV-PCL-MPEG and ACV-PCL-chitosan), they can self-assemble into polymeric 
prodrug micelles in aqueous medium. Here, ACV-PCL acts as the hydrophobic 
segment and MPEG or chitosan serve as the hydrophilic segments. Polymeric 
micelles of ACV-PCL copolymer were prepared via the evaporation method [39]. 
The CMC using pyrene as a hydrophobic fluorescent probe was carried out to 
 
Figure 2.6. FTIR spectra of (A) ACV-PCL, (B) chitosan, and (C) ACV-PCL-chitosan. 
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prove the formation of the micellar structures. Pyrene can preferentially partition 
into the interior hydrophobic microdomains and change the intensities of the first 
and third bands in the pyrene fluorescence spectrum [37] For ACV-PCL-MPEG 
the shift found in the first and third bands was at I335/I330 while for ACV-PCL-
chitosan it was at I337/I332. It is believed that this change is due to different polymer 
compositions. Figure 2.7 A shows the CMC values of ACV-tagged polymeric 
micelles in aqueous medium. It was determined that the CMCs for ACV-PCL-
MPEG and ACV-PCL-chitosan were 2.0 and 6.6 mg L-1, respectively (Figure 2.7 
A (i) and (ii)). Kim et al. reported that the CMC values of block copolymers 
depends upon the block copolymer architecture [40]. In this study, the 
hydrophobic block was kept constant, as ACV-PCL, while the hydrophilic block 
was changed to either MPEG or chitosan. The low CMC value obtained for ACV-
tagged polymeric micelles could provide evidence for their stability in dilute 
solutions. 
 In order to characterize the morphology of ACV-tagged polymeric micelles, 
DLS and TEM analyses were carried out. Figure 2.7 B shows the size and 
morphology of ACV-tagged polymeric micelles. As can be seen from DLS results, 
sizes of the two types of polymeric prodrug micelles were under 200 nm. ACV-
PCL-MPEG (Figure 2.7 B (i)) and ACV-PCL-chitosan (Figure 2.7 B (ii)) micelles 
showed size distributions with mean diameters of 142.8 and 172.7 nm, 
respectively. The morphology of the micelles was further examined by TEM as 
shown in the insets of Figure 2.7 B. The size of the micelles in the TEM images 
was slightly lower than the results from DLS with an average particle size of ~100-
150 nm. This size fluctuation is due to the fact that DLS records the hydrodynamic 
radius of particles which is often times slightly larger than the actual particle size. 
Zeta potential analysis of ACV-tagged polymeric micelles was also performed. 
An average zeta potential for ACV-PCL-MPEG micelles was 1.4 mV. Due to the 
fact that MPEG has a neutral charge, the results obtained for ACV-PCL-MPEG 
micelles are reasonable. In contrast, the detected zeta potential of ACV-PCL-
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chitosan micelles was 32.3 mV. This is attributed to the positive charge of the 
hydrophilic chitosan segment deployed on micellar nanoparticles.  
To determine the drug loading percentage of ACV per mg of micelle 
formulation, the absorbance of ACV-tagged polymeric micelles at t = 0 and t = 48 
h was examined and compared to a standard calibration curve of ACV ranging 
from 0.002 to 1.0 mg/mL. It was found that ACV comprised 8.7% and 3.2% of 
ACV-PCL-MPEG and ACV-PCL-chitosan micelles, respectively. The difference 
in ACV loading percentage is due to different conditions employed for the 
synthesis of ACV-PCL-MPEG and ACV-PCL-chitosan amphiphilic copolymers. 
While MPEG-NH2 can dissolve in organic solvent, chitosan requires an aqueous 
solvent for it to dissolve. Therefore, for ACV-PCL-chitosan synthesis, the ester 
bond between ACV and PCL is already weakened, thereby resulting in less ACV 
 
Figure 2.7.  (A) Plot of the intensity ratio (II/IIII) versus concentration of ACV-tagged 
polymeric micelles, and (B) particle size distribution of (i) ACV-PCL-MPEG and (ii) 
ACV-PCL-chitosan. Insets represent TEM images. 
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coupled with PCL than ACV-PCL-MPEG which is synthesized under organic 
solvent environment. 
2.4.3. In vitro release of ACV from polymeric micelles 
The in vitro release behaviors of ACV from both types of polymeric prodrug 
micelles in PBS at 25oC were studied and the results are shown in Figure 2.8 and 
2.9. A Similar biphasic drug release profile of ACV-PCL-MPEG and ACV-PCL-
chitosan micelles was observed, with initial burst release within the first 2 h (~ 
50% accumulative release) followed by a sustained release pattern up to 48 h. 
The release of ACV from both polymeric prodrug micelles was caused by the 
hydrolysis of ester linkage between ACV and PCL. In the first phase, the rate of 
drug release from ACV-PCL MPEG micelles was relatively rapid than that from 
ACV-PCL-chitosan ones. The reason for this phenomenon is speculated to be 
twofold. First, MPEG chains probably are more hydrophilic and flexible than 
chitosan chains on micellar nanoparticles, leading to a faster hydrolysis and 
 
Figure 2.8. In vitro drug release profile of ACV-PCL-MPEG in PBS (mean ± SD, n = 
3). 
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concomitant ACV diffusion from hydrophobic PCL cores. Second, the diffusion of 
ACV molecules might be slowed down by the positively charged chitosan on 
ACV-PCL-chitosan micelles. Such different initial release trend continued and 
resulted in higher ACV accumulative release from ACV-PCL-MPEG micelles 
(96%) than from ACV-PCL-chitosan micelles (82%). 
The release of ACV from the prodrug tagged micelles was modeled using 
both Langmuir and Power Law models. It can be seen from Figure 2.8 and 2.9, 
that the Power Law was not a good fit for release of ACV from polymeric micelles. 
Here, n was equal to 0.19 and 0.21 in ACV-PCL-MPEG and ACV-PCL-chitosan, 
respectively. The exponent, n, of a sphere with Fickian diffusion as the drug 
release mechanism is 0.43 [41], because our exponents are lower than this value, 
the drug release mechanism of ACV from polymeric micelles is not solely through 
diffusion. This makes sense seeing as we believe that the ester bond between 
prodrug ACV and PCL is broken via hydrolysis. Therefore, first the bond must be 
broken and then ACV can diffuse out of the micelle carrier. In contrast to the 
 
Figure 2.9. In vitro drug release profile of ACV-PCL-chitosan in PBS (mean ± SD, n 
= 3). 
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Power Law, the Langmuir model fit the release of ACV from polymeric micelles 
well. The Langmuir model, is an enzyme kinetics model, and because ACV is 
released via reaction diffusion, the dissolution is taken into account with this 
model. Here, we found that the dissociation constant (Kd) was equal to 1.40 and 
1.14 in ACV-PCL-MPEG and ACV-PCL-chitosan, respectively.  
2.4.4. Cytotoxicity study 
Biocompatibility is a vital necessity of polymer materials being used for drug 
delivery applications. To evaluate if ACV-tagged polymeric micelles showed any 
cytotoxicity towards HT29 colorectal cells, MTT assay was performed. As shown 
in Figure 2.10, the viability of HT29 cells after treatment for 48 h with either ACV-
PCL-MPEG or ACV-PCL-chitosan has little change compared with the untreated 
control cells (i.e., cells without any micelle challenge). These results demonstrate 
that ACV-tagged polymeric micelles do not exhibit apparent toxicity, and are 
biocompatible. 
 
Figure 2.10. Viability of HT29 colorectal cancer cells challenged with ACV-tagged 
polymeric micelles at different dosages.  Control (without micelle challenge),  
ACV-PCL-MPEG micelles, and  ACV-PCL-chitosan micelles (mean ± SD, n = 3). 
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2.5. CONCLUSION 
In this study, ACV-PCL-MPEG and ACV-PCL-chitosan polymeric micelles were 
synthesized and characterized. ACV was used to directly initiate polymerization 
????-CL to form hydrophobic ACV-PCL. Compared to conventional methods of 
incorporating ACV into polymeric carriers by chemical conjugation or physical 
encapsulation, our approach is advantageous in terms of eliminating drug-loading 
steps, enhancing drug-carrying capacity, and decreasing production cost. By 
grafting ACV-PCL with either MPEG or chitosan, ACV-tagged amphiphilic 
polymers can self-assemble as micellar nanoparticles in aqueous medium. 
Structural analyses such as 1H NMR and FTIR were performed to confirm their 
conjugation. ACV-tagged polymeric micelles were found to have a mean size 
under 200 nm by both DLS and TEM and have a low CMC. Moreover, both ACV-
PCL-MPEG and ACV-PCL-chitosan micelles were non-toxic to HT29 colorectal 
cells. ACV-tagged polymeric micelles are potential carriers for therapeutic and 
anticancer drug delivery. 
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CHAPTER 3: GANCICLOVIR INTEGRATED POLYMERIC 
NANOCARRIERS FOR GENE-DIRECTED ENZYME PRODRUG 
THERAPY3 
3.1. ABSTRACT 
The most prominent suicide gene therapy is the use of herpes simplex virus 
thymidine kinase (HSV-TK) in conjunction with guanosine-based prodrug 
ganciclovir (GCV). This is a two-step process whereby first the gene (HSV-TK) is 
delivered to targeted cells and then the prodrug (GCV) is administered where it 
is then activated to its cytotoxic form, GCV-TP by the gene-expressed exogenous 
enzyme. Here, we propose a one-step delivery of gene and prodrug through 
polymeric micellar nanocarriers. In this study, Guanosine-based GCV was used 
as the initiator in ring-opening polymerization of ?-caprolactone to form 
hydrophobic GCV-PCL which was then grafted to hydrophilic chitosan to form 
amphiphilic copolymers for the preparation of stable micellar nanoparticles. 
Successful synthesis of amphiphilic copolymers was followed by 1H NMR and 
FTIR. Self-assembly behavior of micellar nanoparticles was determined by TEM, 
particle size and charge and critical micelle concentration (CMC). Polymeric 
nanocarriers with optimal characteristics encoded with HSV-TK plasmids were 
cultured with parental HT-29 colorectal cancer cells and toxicity measured. 1H 
NMR analysis shows successful synthesis of GCV-PCL. FTIR spectra reveal 
characteristic absorption peaks associated with chitosan and PCL are 
simultaneously present in amphiphilic copolymer GCV-PCL-chitosan. CMC of 
GCV-PCL-chitosan copolymer was measured to be 11.2 mg L-1 while size 
measured by dynamic light scattering was detected to be 93.4 nm, with a zeta 
potential of +38.5 mV. Toxicity results demonstrate that GCV-PCL-chitosan/TK 
nanovectors are a feasible approach to kill HT29 colon cancer cells.  
3.2. INTRODUCTION 
3The material contained in this chapter is planned for publication in Molecules and 
Macromolecular Bioscience. 
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Gene-directed enzyme prodrug therapy (GDEPT) is one of the most important 
and successful prodrug delivery approaches for cancer therapy. In GDEPT, a 
prodrug, a pharmacologically inactive molecule that requires enzymatic and/or 
chemical transformation to release a cytotoxic drug, is given to the patient. The 
prodrug contains the drug which will be used to destroy the targeted cancer cells. 
The gene for a foreign enzyme and the prodrug are administered in a two-step 
process. That is, first the foreign gene is introduced into the targeted cancer cells, 
expressed and released into the cytoplasm and then the prodrug is administered. 
The prodrug is activated by the gene-expressed exogenous enzyme and 
converted to its cytotoxic form [1, 2].  
 The most prominent GDEPT pair is the use of herpes simplex virus 
thymidine kinase (HSV-TK) in conjunction with a variety of guanosine-based 
prodrugs [3-5]. Ganciclovir (GCV) is the most widely used prodrug for HSV-TK, 
and is a well-known antiviral agent [3, 6-8]. The HSV-TK/GCV system has been 
used in the treatment of brain tumors [9, 10], colorectal tumors [11-13], and oral 
cancer [14]. Research has shown that HSV-TK/GCV exhibits not only direct 
cytotoxicity but also a bystander effect, which builds up the efficiency of the HSV-
TK/GCV system in destroying malignant cells [13, 15, 16]. However, significant 
therapeutic benefit has yet to be demonstrated; most likely limited by inefficient 
gene and drug delivery to tumor cells. Most GDEPT studies, and those which 
have reached clinical trials, have been focused on using viral vectors to deliver 
the prodrug and activating gene [17, 18]. However, viruses harnessed in the gene 
therapy field are notorious for causing immunogenicity and tumorigenicity [19]. 
Safety concerns associated with viral vectors have prompted researchers to 
develop non-viral vectors for gene delivery. 
In particular, polymeric nanoparticles have attracted attention because of 
their potential applications in medicine and pharmacy as drug delivery carriers. 
In recent years, polymeric micelles have been the focus of much interest as 
alternative vehicles for the solubilization of poorly water-soluble molecules 
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rendering clear advantages over current solubilizing agents in drug delivery [20]. 
Polymeric micelles are expected to withstand the diluting effect of blood, stay in 
a micellar form and even act as a circulating depot drug delivery system after 
intravenous administration. Moreover, there is no inclusion of potentially harmful 
surfactants and excipients in the process of encapsulating hydrophobic drug 
molecules. Due to the fact that micelles can be specifically synthesized to 
increase a drug’s solubility and bioavailability, they are a model system for 
GDEPT [21-24]. 
??????-caprolactone) (PCL) having been widely used as the core-forming 
hydrophobic segment of nanoparticles was selected as the model polymer for 
this study. PCL is a semi-crystalline linear resorbable aliphatic polyester. It has 
been commonly used in drug delivery systems because it is biodegradable and 
biocompatible [25-27]. PCL is commonly synthesized by ring-opening 
??????????????? ??? ?-caprolactone using an alcohol (R-OH) as an initiator and 
stannous (II) octoate (Sn(Oct)2) as a catalyst [28, 29]. In addition to using R-OH 
as the initiator, methoxy-poly(ethylene oxide) and starch have been employed as 
macroinitiators to form amphiphilic polymers [30, 31]. In this study, prodrug GCV 
possessing hydroxyl groups was used as the initiator to obtain GCV-PCL. Then, 
hydrophilic chitosan was grafted on the hydrophobic GCV-PCL to form the 
amphiphilic block copolymer which already has the drug attached started from 
the ring-opening polymerization. Chitosan is a natural polysaccharide derived 
from deacetylation of chitin. Chitosan’s biocompatible and biodegradable 
features attract much attention in biomedical and pharmaceutical research [25, 
31].  
The synthesized GCV-tagged amphiphilic copolymer can be self-
assembled in aqueous medium to form polymeric prodrug micelles and were 
used to evaluate anticancer effectiveness to HT29/TK cells (cells which 
overexpressed HSV-TK gene plasmid). Moreover, the positive charge endowed 
on the micelles by chitosan was used to bind HSV-TK gene plasmid onto the 
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micelles for a one-step GDEPT cancer therapy to parental HT29 colorectal cells. 
Our results indicate that GCV-PCL-chitosan/TK micelles are effective carriers for 
GDEPT. 
3.3. MATERIALS AND METHODS 
3.3.1. Materials 
GCV was purchased from TCI (Tokyo, Japan). N,N’-dicyclohexyl carbodiimide 
??????? ?-CL, pyrene, and succinic anhydride were purchased from Acros 
Organics (Geel, Belgium). Sn(Oct)2, CDCl3 with 1% tetramethylsilane (TMS), 
deuterated dimethyl sulfoxide (DMSO-d6), dimethyl sulfoxide (DMSO), 
tetrahydrofuran (THF), dichloromethane (DCM), methanol, 2-propanol, hexane, 
toluene, and chitosan oligosaccharide lactate (MW = 5,000) were all purchased 
from Sigma-Aldrich (St. Louis, MO). Ethyl ether was purchased from J.T. Baker 
(Austin, TX). N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar (Ward 
Hill, MA). Acetone was purchased from Pharmco-AAPER (Shelbyville, KY). 
Pyridine and hydrochloric acid (HCl) were purchased from EMD (Philadelphia, 
PA). Sodium chloride (NaCl) and magnesium sulfate were purchased from 
Showa (Tokyo, Japan). All reagents were used as received without further 
purification. 
3.3.2. Characterization methods 
Gel permeation chromatography (GPC) analyses were performed on a Waters 
1525 binary HPLC pump equipped with a Waters 2414 refractive index detector 
(Milford, MA). Waters styragel HR 3 (MW = 500 – 30,000) and HR 4E (MW = 50 
– 100,000) columns were equipped. Molecular weight calibration was performed 
with polystyrene standards that covered a MW range of 400 – 4.3 × 104. GPC 
analyses were performed in THF at a flow rate of 1 mL min-1 with an injected 
volume of 50 μl. 1H NMR spectra were obtained from a Varian Unity/Inova 400 
MHz instrument (Sparta, NJ). To obtain FTIR spectra by a Jasco FTIR-4200 
spectrometer (Tokyo, Japan), a small amount of polymeric sample was loaded 
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onto a silicon wafer and THF was added dropwise to dissolve the sample and 
evaporated afterwards. This was repeated until the entire sample was dissolved 
and a film had formed. 
3.3.3. Synthesis of GCV-tagged amphiphilic polymers 
G???????????????????????????????????????-CL (2.25 mL) under a sonication 
bath for 5 min at room temperature. Sn(Oct)2 ??????? ?????-CL) was then added 
into the mixture. The entire solution was placed into a 3-necked round-bottom 
flask. The system was purged with nitrogen and immersed in an oil bath at 140oC 
for 24 h. The crude product was cooled to room temperature, dissolved in DCM, 
and precipitated by cold methanol. The product was then vacuum dried by a 
rotary evaporator at 40oC. 
GCV-PCL (0.5 mmol) and succinic anhydride (1 mmol) were weighed and 
dissolved in toluene in a 3-necked round-bottom flask. One mmol pyridine was 
added and the solution was reacted under nitrogen at 70oC for 48 h. The product 
was then precipitated by cold hexane, and spun down. The pellet was re-
dissolved in DCM and washed twice each with 10% (v/v) HCl and saturated NaCl 
solution. The organic phase was isolated and dried with magnesium sulfate then 
filtered. The carboxylated GCV-PCL was recovered by precipitation in cold 
hexane and then vacuum dried by rotary evaporation at 40oC. 
GCV-PCL-COOH (0.54 mmol) and NHS (2.7 mmol) were weighed and 
mixed in 15 mL DCM, and then DCC (2.7 mmol) was added. The reaction was 
run under a nitrogen environment at room temperature for 24 h. The precipitated 
byproduct 1,3-dicyclohexylurea was removed by vacuum filtration. The filtrate 
was added into 35 mL diethyl ether and cooled to 4oC for 4 h to precipitate GCV-
PCL-NHS. The precipitate was collected by centrifugation at 3,500 rpm for 5 min, 
washed with 2-propanol and solvent removed by rotary evaporation at 40oC. 
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GCV-PCL-NHS (10 mg) was dissolved in 5 mL acetone and slowly added 
to chitosan solution (20 mg chitosan oligosaccharide lactate dissolved in 25 mL 
deionized water). The mixture, purged with nitrogen, was stirred in a round-
bottom flask for 24 h. The reacted solution was vacuum dried to remove acetone 
and then lyophilized. The amphiphilic polymer was then dissolved in DCM and 
dialyzed (MWCO = 6-8 kD, Spectra/Por) against pure DCM to remove unreacted 
chitosan. ACV-PCL-chitosan was recovered by rotary evaporation at 40oC. 
3.3.4. Preparation of polymeric prodrug micelles 
GCV-PCL-chitosan micelles and control MPEG-PCL-chitosan micelles were 
formed similarly. Briefly, 10 mg of GCV-tagged amphiphilic polymer was 
dissolved in 2 mL acetone. The solution was then added dropwise to 10 mL 
deionized water under sonication. Acetone was removed by rotary evaporation 
and the final solution was collected by filtering through a 0.45 μm filter. 
3.3.5. Determination of critical micelle concentration 
The CMC was estimated by using pyrene as a fluorescent probe [32]. Briefly, 1 
mg mL-1 of polymeric prodrug micelle was formed. Various amounts of deionized 
water and micellar solution were added respectively to glass vials to obtain 
micellar concentrations ranging from 5 × 10-7 to 1 mg mL-1. Pyrene in acetone 
was then added separately to the prepared vials to get a final concentration of 
pyrene in water of 6.0 × 10-7 mg mL-1, slightly lower than the saturation solubility 
of pyrene in water [33]. The solutions were then allowed to equilibrate for 8 h. 
Fluorescent spectra were determined by a plate reader (Synergy MX, BioTek, 
Winooski, VT) with an excitation wavelength of 334 nm. 
3.3.6. Size and morphology of polymeric prodrug micelles 
The average particle size of polymeric prodrug micelles was determined by a 
dynamic light scattering (DLS) instrument (Zetasizer Nano ZS, Malvern 
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Instruments, United Kingdom) equipped with a red laser at a wavelength of 633 
nm and scattering angle of 90o at 25oC. The zeta potential of the micelles 
dispersed in deionized water was determined with a zeta potential analyzer 
(Zetasizer Nano ZS). Transmission electron microscopy (TEM) image of micelles 
was performed on a JEM-4000FX (JEOL, Tokyo, Japan) at 80 kV. The TEM 
samples were prepared by adding 10 μL of micellar solution (1 mg mL-1) onto a 
Formvar grid for 5 min and wicking away solution in excess. The samples were 
negatively stained with 10 μL phosphotungstic acid solution (2 wt%) for 10 sec 
and then 15 sec, wicking away excess staining solution each time. 
3.3.7. Drug release kinetics 
Polymeric prodrug micelles at a concentration of 1 mg mL-1 were made in 
phosphate buffered saline (PBS) (1 M, pH 7.4) at 25oC.  Two mL of solution was 
placed in a dialysis tube (Float-A-Lyzer, Spectra/Por) with a MWCO of 3.5 – 5 
kD. The dialysis bag was then immersed in 50 mL PBS at 37oC with and without 
esterase (3 units/2 mL). At specified time intervals, 5 μL of sample was removed 
and replaced with fresh PBS. The amount of GCV released was analyzed by a 
plate reader (BioTek) at 254 nm. All experiments were carried out in triplicate. 
3.3.8. Establishing TK-overexpressed HT29 cells 
Human colorectal HT29 cells (HTB-38; ATCC, Manassas, VA) were plated at a 
cell density of 6 x 105, and incubated with 2.5 μL TK plasmid DNA and 5 μL 
TransIT-2020 transfection reagent (Mirus, Madison, WI). After 48 h, cells were 
trypsinized and suspended in fresh medium containing 400 μg mL-1 G418 
antibiotic (Invitrogen, Grand Island, NY). Cells were selected for several weeks 
in order to obtain a stable TK overexpressing HT29 cell line (termed HT29/TK). 
3.3.9. Development of GCV-PCL-chitosan/TK nanovectors 
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In preparation for one-step delivery of both prodrug and gene to cells, GCV-PCL-
chitosan/TK nanovectors were prepared. Here, GCV-PCL-chitosan micelles were 
prepared as previously described. To 1 mL aliquots of micelle solution various 
amounts of TK DNA solution (1.5 – 10.5 μg DNA) was added. The solution was 
vortexed briefly and then allowed to incubate at room temperature for 30 min 
before DLS and zeta measurements were taken. 
3.3.10. Cytotoxicity studies 
24-well plates were seeded with HT29 colorectal cells suspended in 0.5 mL 
Dulbecco’s modified Eagles’ medium (DMEM, Corning Cellgro, Manassas, VA) 
supplemented with 10% fetal bovine serum (FBS, Atlanta biologicals, Flowery 
Branch, GA) and 1% penicillin-streptomycin (Sigma) and incubated at 37oC in 5% 
CO2 balanced with humidified air for 24 h. For two-step delivery cytotoxicity 
studies, parental HT29 and TK gene transfected HT29 cells (HT29/TK) were 
challenged with various concentrations of GCV-PCL-chitosan micelle solution. 
Similarly, for one-step cytotoxicity studies, HT29 parental cells were treated with 
GCV-PCL-chitosan/TK nanovectors (GCV-PCL-chitosan micelles complexed 
with TK gene plasmid). After incubation for 72 h, cell viability was assessed using 
MTT assay. 200 μL of sterile MTT solution (4 mg mL-1) was added into the culture 
wells and incubated for 4 h. The medium containing unreacted MTT was removed 
and 300 μL DMSO was added to dissolve the insoluble purple formazan crystals 
formed in cellular mitochondria. The absorbance at 590 nm was measured with 
a plate reader (BioTek) and results were recorded as viability percentage 
calculated against the control group without micellar challenge. All experiments 
were carried out in triplicate.  
3.4. RESULTS AND DISCUSSION 
3.4.1. Synthesis and characterization of amphiphilic prodrug polymers 
GCV-PCL was synthesized through ring-opening polymerization of ?-CL 
exclusively by GCV (Figure 3.1 A). The 1H NMR spectra of prodrug GCV and 
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GCV-PCL are shown in Figure 3.2 (i) and (ii), respectively. ??????????????????????
1.37 (3-CH2), 1.62 (2-CH2), 2.27 (1-CH2) and 4.04 (4-CH2) ppm correspond with 
??????????????????????????????????????????????????????? f-CH2), 5.47 (d-CH2) 
and 7.76 (b-CH) are assigned to protons in GCV. Evidence of GCV grafting to 
PCL is clearly seen by the characteristics resonances observed in the 
synthesized polymer, confirming the synthesis of GCV-PCL. 
 GCV-PCL was further conjugated with chitosan as shown in Figure 3.1 B-
D. Successful conjugation of chitosan was confirmed by analytical means. Table 
3.1, shows the GPC data concerning the formation of amphiphilic copolymer 
GCV-PCL-chitosan. The increase in number-average molecular weight (Mn) from 
11 kDa to 17 kDa corresponds with the addition of chitosan (MW = 5000).  
 
Figure 3.1. Synthetic scheme of (A) GCV-PCL, (B) GCV-PCL-COOH, (C) GCV-PCL-
NHS, and (D) GCV-PCL-chitosan. 
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 Table 3.1. Characterization of GCV-PCL-chitosana 
Sample Mw 
(Da) 
Mn 
(Da) 
Polydispersity 
(Mw/Mn) 
GCV-PCL 12996 11454 1.13 
GCV-PCL-chitosan 20354 17231 1.18 
aMeasured by GPC 
 
Figure 3.2. 1H NMR spectra of (i) GCV and (ii) GCV-PCL. 
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Furthermore, as shown in Figure 3.3, 1H NMR analysis showed successful 
conjugation of chitosan to GCV-PCL hydrophobic polymer. As shown in Figure
3.1 D, conjugation of chitosan to GCV-PCL is made via amide linkage. The peak 
at 1.79 (A-NH2) from a singlet to a multiplet in Figure 3.3 (iv) confirms conjugation 
of chitosan to GCV-PCL. Moreover, the peaks from the aromatic protons on C3 – 
C6 of chitosan ??????????????????????????– 3.85, slightly shifted downward from 
the peaks shown in the original chitosan sample (Figure 3.3 (iii)). 
 Figure 3.4, depicts the FTIR spectra of GCV-PCL (A), chitosan (B), and 
GCV-PCL-chitosan. OH stretching from 3604 – 3167 cm-1 as well as peaks at 
1634 cm-1 and 1295 cm-1 corresponding to the N-H bending vibrations of the 
primary and secondary amine attributed to chitosan and GCV, respectively. The 
aforementioned peaks as well as the carbonyl absorption at 1721 cm-1 associated 
with PCL and a peak at 1044 cm-1 (C-O-C) seen in each spectra are found in 
GCV-PCL-chitosan. The FTIR results are in line with the results from 1H NMR 
and demonstrate successful synthesis of GCV-PCL-chitosan. 
 
Figure 3.3. 1H NMR spectra of (iii) chitosan and (iv) GCV-PCL-chitosan. 
79 
 3.4.2. Formation and characterization of GCV-tagged polymeric micelles 
Through the solvent evaporation method, polymeric micelles of GCV-PCL-
chitosan were formed. Here, the hydrophobic core segment was GCV-PCL and 
chitosan was the cationic and hydrophilic corona segment. Utilizing pyrene has a 
hydrophobic fluorescent probe, the critical micelle concentration (CMC) of GCV-
PCL-chitosan micelles was examined. Pyrene can preferentially partition into the 
interior hydrophobic microdomains and change the intensities of the first and third 
bands in the pyrene fluorescence spectrum [33]. A low critical micelle 
concentration is indicative that the micellear solution are stable at high dilutions. 
For GCV-PCL-chitosan, the shift of the first and third bands was found at I338/I329. 
The CMC was determined to be 11.2 mg L-1 (Figure 3.5 A). 
 
Figure 3.4. FTIR spectra of (A) GCV-PCL, (B) chitosan, and (C) GCV-PCL-chitosan. 
80 
 The morphology of GCV-PCL-chitosan micelles was examined through 
DLS and TEM analysis. Figure 3.5 (B) shows the size and morphology of GCV-
tagged polymeric micelles. The average size as reported by DLS was 93.4 nm 
with a zeta potential of 38.5 mV. The positive charge is attributed to chitosan used 
as the hydrophilic segment on the micelle carriers. TEM analysis are shown in 
the insets of Figure 3.5 (B). The size of the micelles in the TEM images was 
around 100 nm. The results from DLS and TEM show good agreement. 
 After formation of GCV-PCL-chitosan, various concentrations of TK DNA 
plasmid was incubated with 1 mL of micelle solution. Due to ionic interactions, 
the negatively charged TK DNA was able to form a complex with the positively 
charged chitosan used as the hydrophilic segment in micelle nanocarriers. Size 
and charge was measured by DLS and the results are shown in Table 3.2. As 
can be seen from DLS results, when the DNA was given 30 min to complex with 
the micelles, the size of GCV-PCL-chitosan micelles was relatively stable 
increasing only to 146 nm with the addition of 10.5 μg TK DNA. Charge began to 
decrease from 38.5 mV to 28.2 mV with the addition 0 and 3 μg TK DNA, 
respectively. However, after the addition of 4.5, 7.5 and 10.5 μg TK DNA the 
charge did not continue to decrease as expected. 
Figure 3.5. (A) Plot of the intensity ratio (II/IIII) versus concentration of GCV-PCL-
chitosan micelles and (B) particle size distribution of GCV-PCL-chitosan. Insets 
represent TEM images. 
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Table 3.2. Size and charge of GCV-PCL-chitosan after addition of TK DNA as measured 
by zetasizer 
Amount of DNA 
(μg) Size (nm) 
Zeta Potential 
(mV) 
0 93.4 38.5 
1.5 92.4 37.9 
2 92.4 30.1 
3 92.8 28.2 
4.5 128.4 37.5 
7.5 177.5 35.0 
10.5 146 33.9 
 To determine the drug loading percentage of GCV per mg of prepared 
micelle solution, the absorbance of GCV-PCL-chitosan was examined at t = 0 
and t = 72 h and compared to a standard calibration curve of GCV ranging from 
0.002 to 1.0 mg mL-1. It was found that GCV comprised 4.8% of the micelles. 
3.4.3. In vitro release of GCV from polymeric micelles 
The in vitro release behavior of GCV at 37oC with and without esterase was 
studied. To mimic cellular conditions, esterase at a concentration of 3 units/2 mL 
was used [34]. As can be seen from Figure 3.6, the release of GCV with esterase 
was much quicker than without reaching a maximum release of 81% within 30 h. 
In contrast it took 48 h without esterase for GCV to reach a maximum release of 
77% (Figure 3.7). Moreover, it took up to 2 h before a substantial difference in 
the release rate was seen. This is due to the time needed for esterase to diffuse 
into the micelle core and for activation. 
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 The release of GCV from GCV-PCL-chitosan was modeled using both 
Power Law and Langmuir models. As can be seen from Figure 3.6 and 3.7, Power 
Law was not a good fit for the release of GCV from polymeric micelles. Here, the 
exponent, n, was equal to 0.18 and 0.29 in GCV-PCL-chitosan micelles with and 
without esterase, respectively. Similar to the release of ACV in Chapter 2, the 
drug release mechanism does not occur solely though diffusion [35]. Here, 
without esterase, GCV release will occur by hydrolysis of the ester bond. The 
release rate is increased by the addition of esterase to GCV-PCL-chitosan which 
in addition to hydrolysis will break the ester bond. Due to the fact that GCV 
release occurs through reactive diffusion, the Langmuir model was also chosen 
for fitting the data. As can be seen in Figure 3.6 and 3.7, the release of GCV from 
GCV-PCL-chitosan with and without esterase using the Langmuir model fits the 
experimental data well. In addition, the dissociation constant (Kd) for release of 
GCV from GCV-PCL-chitosan, was found to be 1.18 and 2.79 with and without 
esterase, respectively. Relating this data to the release of ACV in Chapter 2 leads 
 
Figure 3.6. In vitro drug release profile of GCV from GCV-PCL-chitosan in PBS at 
37oC with esterase (3 units/ 2 mL) (mean ± SD, n = 3). 
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to several conclusions. First, GCV has a stronger association to PCL then ACV 
(K = 2.79 and 1.14, respectively). Secondly, the addition of esterase will increase 
the release rate to a similar release to ACV. We hypothesized that the increase 
in the dissociation constant was due to GCV having two reactive points to initiate 
ring-opening polymerization of ?-CL compared to ACV which only has one. In our 
results with 5’DFUR (Chapter 3), a similar trend to GCV release was seen, 
confirming our hypothesis.    
3.4.4. Cytotoxicity studies 
To examine the potential of GCV for suicide gene therapy, HT29 colorectal cells 
were transfected with HSV-TK gene plasmid. The growth of both parental HT29 
and HT29/TK cells are shown in Figure 3.8. It can be seen that the growth kinetics 
revealed that both HT29 and HT29/TK cells followed a similar growth rate after 
transfection and selection of a stable transfected cell line was not altered. 
 
Figure 3.7. In vitro drug release profile of GCV-PCL-chitosan in PBS at 37oC (mean 
± SD, n = 3). 
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 After obtaining a stable transfected cell line, HT29 and HT29/TK cells were 
challenged with GCV-tagged polymeric prodrug micelles. Through MTT assay, 
cytotoxicity of GCV-PCL-chitosan polymeric micelles ranging in centration of 25 
to 250 μg mL-1 for 24, 48 and 72 h were investigated. Due to the fact that parental 
HT29 cells do not have any endogenous TK gene plasmid to convert GCV to its 
toxic form, cell viability was not affected (Figure 3.9 A). In contrast, HT29/TK cells 
which had upregulated TK gene expression showed cell death up to 35% at a 
dosage of 250 μg mL-1 for 72 h treatment (Figure 3.9 B). These results confirmed 
that GCV can be converted to its active and toxic form via overexpressed TK 
gene in colon cancer cells for the classical two-step treatment.
 
  
 
Figure 3.8. Cell growth kinetics profiles of HT29 ( ) and HT29/TK ( ). 
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Figure 3.9. Cell viability after treatment with GCV-PCL-chitosan micelles (A) 
parental HT29, and (B) HT29/TK cells. 
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In an effort to examine the feasibility of a one-step anticancer therapy, TK 
DNA (1.5 and 6 μg) was complexed onto GCV-PCL-chitosan micelles via ionic 
interactions. Here, expression of the gene plasmid and subsequent toxicity was 
followed for three days and five days. As can be seen in Figure 3.10, expression 
of the plasmid in the cells after three days was sufficient to cause cell death. An 
additional two days did not cause a significant increase in cell toxicity. Moreover, 
it was seen that when TK gene plasmid was complexed onto control micelles 
(MPEG-PCL-chitosan), no cell toxicity was observed. These observations are 
expected because the micelle alone is not toxic to the cells, it is the prodrug GCV 
converted to its cytotoxic form by HSV-TK which causes cell death. From these 
results, subsequent one-step studies were carried out with 3 days for gene 
expression and subsequent toxicity. 
Figure 3.10. Expression of HSV-TK gene plasmid. 1.5 and 6 μg HSV-TK DNA was 
complexed onto GCV-PCL-chitosan and MPEG-PCL-chitosan micelles and the 
gene expression followed for 3 ( ) and 5 ( ) days. 
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After expression studies, parental HT29 cells were then treated with 
various concentrations of GCV-PCL-chitosan/TK nanovectors complexed with 
1.5 - 10.5 μg TK DNA and cytotoxicity observed as shown in Figure 3.11. Toxicity 
followed a similar trend to what was expected. By increasing the amount of DNA, 
there is more conversion of GCV to its cytotoxic form and therefore, more cell 
death. In this study, cell viability was decreased to around 52% with a micelle 
concentration of 250 μg mL-1 and 4.5 μg DNA. It appears that 4.5 μg TK DNA is
the upper limit for DNA complexation with GCV-PCL-chitosan micelles. 
Increasing the TK DNA amounts to 7.5 and 10.5 μg did not show an increase in 
cell death. 
 
Figure 3.11. One-step delivery of gene and prodrug. Parental HT29 cells were 
challenged with 250 ( ), 75 ( ), and 25 ( ) μg mL-1 GCV-PCL-chitosan/TK 
nanovectors for 3 days. 
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3.5. CONCLUSION 
GDEPT is a promising gene therapy method to combat cancer. However, 
developing an efficient carrier for both the gene and prodrug required for 
enhanced cancer therapy. In this study, we have developed a micelle carrier 
which achieved both of these goals, sufficient gene and prodrug delivery. 
Moreover, our polymer micelle carriers deliver both the gene and prodrug 
simultaneously, which is ideal for patients. Our results indicate that GCV-PCL-
chitosan nanocarriers can reduce viability of HT29 colorectal cells by 52% in a 
one-step approach. Developing similar drug nanocarriers could have broad 
impact and enhance the effectiveness of GDEPT. 
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CHAPTER 4: ENHANCED ANTICANCER ACTIVITY OF 
5’DFUR-PCL-MPEG POLYMERIC PRODRUG MICELLES 
ENCAPSULATING CHEMOTHERAPEUTIC DRUGS4 
4.1. ABSTRACT 
In this study, chemotherapy prodrug 5-doxifluridine (5’-DFUR) associated with 
amphiphilic copolym??? ??????-caprolactone)-methoxy poly(ethylene glycol) (5’-
DFUR-PCL-MPEG) was synthesized, characterized, and self-assembled into 
functional polymeric micelles. To demonstrate that prodrug 5’-DFUR could 
convert into cytotoxic 5-fluorouracil (5-FU) by endogenous thymidine 
phosphoylase (TP), HT29 colon cancer cells were treated with 5’-DFUR-PCL-
MPEG polymeric micelles for various time periods and showed up to 40% cell 
death rate after 72 h treatment. In contrast, HT29 cells challenged with 5’-DFUR-
tagged polymeric micelles which encapsulated DOX or SN-38, chemotherapeutic 
drugs, remained only 36% and 31% in cell viability. Our results demonstrated that 
the developed 5’-DFUR-PCL-MPEG polymeric micellar nanoparticles have the 
potential for gene-directed enzyme prodrug therapy. 
4.2. INTRODUCTION 
5-Fluorouracil (5-FU) is one of the main anti-tumor agents used to treat colon, 
breast and gastric cancers. Due to the short plasma half-life of 5-FU, it is often 
administered to patients through continuous infusion [1]. 5-FU however, is poorly 
tumor selective and its therapy causes several severe adverse side effects in 
patients including intestinal discomfort. To circumvent toxicity, 5-doxifluridine (5’-
DFUR), a prodrug of 5-FU, is commonly administered to patients [2]. 5’-DFUR is 
converted to its active and toxic form 5-FU through metabolic conversion by 
thymidine phosphorylase (TP), a gene overexpressed in many cancer types [3]. 
Several groups have exploited the enzyme-prodrug activation model of TP and 
4The material contained in this chapter is planned for publication in The Journal of 
Controlled Release. 
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5’-DFUR and shown that by transfection of cancer cell lines with TP, sensitivity 
of  tumor cells to this prodrug is enhanced by the increased TP expression [4, 5]. 
Clinically, 5’-DFUR has been established for treatment of various cancer 
types [6-8]. Moreover, several studies have evaluated combination therapies of 
5’-DFUR with other chemotherapy drugs such as tamoxifen, 
medroxyprogesterone acetate, and docetaxel with successful results [9-11]. 
While 5’-DFUR itself is slightly hydrophilic, intrinsic issues that are associated 
with other “free drugs,” such as poor solubility, unwanted toxicity, and short 
circulation times have propelled research into alternative drug delivery systems. 
There are several factors which contribute to success of a synthesized 
therapeutic carrier. One must first address the physiochemical limitations of the 
drugs; second, one needs to address the biological hurdles in reaching the 
targeted tumorous tissue. Polymeric nanocarriers for drug delivery are being 
developed for a wide variety of cancers and chemotherapeutic drugs [12-14]. 
Specifically, several polymeric micelle carriers which house hydrophobic 
chemotherapy drugs doxorubicin (DOX), paclitaxel or 7-ethyl-10-
hydroxycamptothecrin (SN-38) in their core are advancing into clinical trials with 
great success [15-17]. 
SN-38 is a biologically active metabolite of irinotecan hydrochloride (CPT-
11). While CPT-11 is a prodrug which can be converted to SN-38 by 
carboxylesterases, SN-38 has shown to have 1,000-fold more potent toxicity 
towards various cancer cells in vitro [18]. Moreover, metabolic conversion of 
CPT-11 to SN-38 in the liver and tumor has shown to be less than 10% of its 
original volume [19, 20]. Therefore, direct use of SN-38 is advantageous for 
cancer treatment. Similarly, DOX is another widely used antitumor drug effective 
in the treatment of carcinomas of the breast, lung, thyroid and colon. However, 
due to the ensuing toxicity and low water solubility of free SN-38 and DOX, use 
of a drug carrier is warranted. 
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It has been shown previously that the hydroxyl groups on 5’DFUR can be 
used for initiation in the ring-?????????????????????????? ?-caprolactone to form 
hydrophobic 5’-DFUR-polycaprolactone (5’-DFUR-PCL) [21]?? ??????-
caprolactone) (PCL) is commonly used for biomedical applications because of its 
excellent biodegradability and biocompatibility [22]. In this study, we further 
grafted hydrophobic 5’-DFUR-PCL with hydrophilic biodegradable methoxy 
poly(ethylene glycol) MPEG, widely used for drug delivery to form amphiphilic 
copolymers for micelle preparation [23-25]. Moreover, because camptothecin-
based drugs are often used in conjunction with 5-FU as a first therapy [26], and 
the anticancer effectiveness of DOX, we encapsulated SN-38 or DOX into our 
prodrug-tagged polymeric micelles for an additive anticancer therapy. 
To evaluate anticancer effectiveness of our synthesized polymeric micelle 
carriers, HT29 colon cancer cells, which express endogenous TP levels, were 
treated with our micelle carrier. Moreover, SN-38 and DOX, chemotherapeutic 
drugs, used to treat a wide variety of cancer types, were encapsulated into our 
micelle carriers and the additive effect of both 5’DFUR and chemotherapeutic 
drugs on HT29 cell death was examined. Our results indicate that 5’-DFUR-PCL-
MPEG micelle carriers are an effective and efficient means to deliver 5’DFUR 
and chemotherapeutic drugs to tumor cells. 
4.3. MATERIALS AND METHODS 
4.3.1. Materials 
5’-DFUR was purchased from Tokyo Chemical Industry Co. Ltd. (TCI, Japan). 
N,N’-????????????? ???????? ???? ??????? ?-CL, pyrene, and succinic anhydride 
were purchased from Acros Organics (Geel, Belgium). Sn(Oct)2, CDCl3 with 1% 
tetramethylsilane (TMS), deuterated dimethyl sulfoxide (DMSO-d6), dimethyl 
sulfoxide (DMSO), tetrahydrofuran (THF), dichloromethane (DCM), methanol, 2-
propanol, hexane, toluene, SN-38, DOX, methoxypolyethylene glycol amine 
(MPEG-NH2; MW = 5,000), and MPEG (MW = 350) were all purchased from 
Sigma-Aldrich (St. Louis, MO). Ethyl ether was purchased from J.T. Baker 
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(Austin, TX). N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar (Ward 
Hill, MA). Acetone was purchased from Pharmco-AAPER (Shelbyville, KY). 
Pyridine and hydrochloric acid (HCl) were purchased from EMD (Philadelphia, 
PA). Sodium chloride (NaCl) and magnesium sulfate were purchased from 
Showa (Tokyo, Japan). All reagents were used as received without further 
purification. 
4.3.2. Characterization methods 
Gel permeation chromatography (GPC) analyses were performed on a Waters 
1525 binary HPLC pump equipped with a Waters 2414 refractive index detector 
(Milford, MA). Waters styragel HR 3 (MW = 500 – 30,000) and HR 4E (MW = 50 
– 100,000) columns were equipped. Molecular weight calibration was performed 
with polystyrene standards that covered a MW range of 400 – 4.3 × 104. GPC 
analyses were performed in THF at a flow rate of 1 mL min-1 with an injected 
volume of 50 μl. 1H NMR spectra were obtained from a Varian Unity/Inova 400 
MHz instrument (Sparta, NJ). To obtain FTIR spectra by a Jasco FTIR-4200 
spectrometer (Tokyo, Japan), a small amount of polymeric sample was loaded 
onto a silicon wafer and THF was added dropwise to dissolve the sample and 
evaporated afterwards. This was repeated until the entire sample was dissolved 
and a film had formed. 
4.3.3. Synthesis of 5’DFUR-tagged amphiphilic polymers 
5’DFUR ???? ??????????????????? ???????????-CL (2.25 mL) under a sonication 
bath for 5 min at room temperature. Sn(Oct)2 ??????? ?????-CL) was then added 
into the mixture. The entire solution was placed into a 3-necked round-bottom 
flask. The system was purged with nitrogen and immersed in an oil bath at 140oC 
for 24 h. The crude product was cooled to room temperature, dissolved in DCM, 
and precipitated by cold methanol. The product was then vacuum dried by a 
rotary evaporator at 40oC. 
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5’DFUR-PCL (0.5 mmol) and succinic anhydride (1 mmol) were weighed 
and dissolved in toluene in a 3-necked round-bottom flask. One mmol pyridine 
was added and the solution was reacted under nitrogen at 70oC for 48 h. The 
product was then precipitated by cold hexane, and spun down. The pellet was re-
dissolved in DCM and washed twice each with 10% (v/v) HCl and saturated NaCl 
solution. The organic phase was isolated and dried with magnesium sulfate then 
filtered. The carboxylated 5’DFUR-PCL was recovered by precipitation in cold 
hexane and then vacuum dried by rotary evaporation at 40oC. 
5’DFUR-PCL-COOH (0.54 mmol) and NHS (2.7 mmol) were weighed and 
mixed in 15 mL DCM, and then DCC (2.7 mmol) was added. The reaction was 
run under a nitrogen environment at room temperature for 24 h. The precipitated 
byproduct 1,3-dicyclohexylurea was removed by vacuum filtration. The filtrate 
was added into 35 mL diethyl ether and cooled to 4oC for 4 h to precipitate 
5’DFUR-PCL-NHS. The precipitate was collected by centrifugation at 3,500 rpm 
for 5 min, washed with 2-propanol and solvent removed by rotary evaporation at 
40oC. 
5’DFUR-PCL-NHS (10 mg) and MPEG-NH2 (10 mg) were weighed and 
dissolved by 20 mL DCM in a round-bottom flask. The flask was purged with 
nitrogen and the solution was stirred for 24 h. The solution was then dialyzed 
(MWCO = 6-8 kD, Spectra/Por, Rancho Dominguez, CA) against pure DCM to 
remove remaining MPEG-NH2. 5’DFUR-PCL-MPEG was recovered by rotary 
evaporation at 40oC. 
4.3.4. Preparation of polymeric prodrug micelles 
5’DFUR-PCL-MPEG and chemotherapy drug loaded 5’DFUR-PCL-MPEG 
micelles were formed similarly. Briefly, 10 mg of 5’DFUR-tagged amphiphilic 
polymer, with or without 0.2 mg DOX or 0.1 mg SN-38, were dissolved in 2 mL 
acetone under bath sonication. The solution was then added dropwise to 10 mL 
deionized water under bath sonication. Acetone was removed by rotary 
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evaporation and the final solution was collected by filtering through a 0.45 μm 
filter. 
4.3.5. Determination of critical micelle concentration 
The critical micelle concentration (CMC) was estimated by using pyrene as a 
fluorescent probe [27]. Briefly, 1 mg mL-1 of polymeric prodrug micelle was 
formed. Various amounts of deionized water and micellar solution were added 
respectively to glass vials to obtain micellar concentrations ranging from 5 × 10-7 
to 1 mg mL-1. Pyrene in acetone was then added separately to the prepared vials 
to get a final concentration of pyrene in water of 6.0 × 10-7 mg mL-1, slightly lower 
than the saturation solubility of pyrene in water [28]. The solutions were then 
allowed to equilibrate for 8 h. Fluorescent spectra were determined by a plate 
reader (Synergy MX, BioTek, Winooski, VT) with an excitation wavelength of 334 
nm. 
4.3.6. Size and morphology of polymeric prodrug micelles 
The average particle size of polymeric prodrug micelles was determined by a 
dynamic light scattering (DLS) instrument (Zetasizer Nano ZS, Malvern 
Instruments, United Kingdom) equipped with a red laser at a wavelength of 633 
nm and scattering angle of 90o at 25oC. The zeta potential of the micelles 
dispersed in deionized water was determined with a zeta potential analyzer 
(Zetasizer Nano ZS). Transmission electron microscopy (TEM) image of micelles 
was performed on a JEM-4000FX (JEOL, Tokyo, Japan) at 80 kV. The TEM 
samples were prepared by adding 10 μL of micellar solution (1 mg mL-1) onto a 
Formvar grid for 5 min and wicking away solution in excess. The samples were 
negatively stained with 10 μL phosphotungstic acid solution (2 wt%) for 10 sec 
and then 15 sec, wicking away excess staining solution each time. 
4.3.7. Drug loading content and entrapment efficiency 
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To determine the drug loading percentage of 5’DFUR per mg of micelle 
formulation, the absorbance of 5’DFUR-PCL-MPEG micelles at t=0 and t=72 h 
was examined ????????????????and compared to a standard calibration curve of 
5’DFUR ranging from 0.002 to 1.0 mg mL-1. To obtain drug loading content and 
entrapment efficiency of DOX or SN-38 encapsulated in micelles, the obtained 
micellear solutions were frozen and lyophilized by a freezer dryer system to 
obtain dried nanoparticle product. The weighed nanoparticles were dissolved in 
chloroform/DMSO (1:1, v/v) and the absorbance of the solutions read at 485 nm 
(DOX) or 366 nm (SN-38) using a plate reader. The weight of the entrapped drug 
was calculated by a calibration curve from 0.01 mg mL-1 to 1 mg mL-1. Drug 
loading content and entrapment efficiency were determined by equations (1) and 
(2), respectively: 
 Drug loading content (%)  = weight of drug in nanoparticlesweight of nanoparticles × 100  (1) 
 Entrapment efficiency (%) = weight of drug in nanoparticlesweight of drug fed initially × 100   (2) 
4.3.8. Drug release kinetics 
Polymeric prodrug micelles at a concentration of 1 mg mL-1 were made in 
phosphate buffered saline (PBS) (1 M, pH 7.4) at 37oC.  2 mL of solution was 
placed in a dialysis tube (Float-A-Lyzer, Spectra/Por) with a MWCO of 3.5 – 5 
kD. The dialysis bag was then immersed in 50 mL PBS at room temperature and 
370C with and without esterase (3 units/2 mL) to mimic cellular conditions. At 
specified time intervals, 5 μL of sample was removed and replaced with fresh 
PBS. The amount of 5’DFUR released was analyzed by a plate reader (BioTek) 
at 269 nm. All experiments were carried out in triplicate. 
4.3.9. Cytotoxicity studies 
24-well plates were seeded with human colorectal HT29 cells (HTB-38; ATCC, 
Manassas, VA) suspended in 0.5 mL Dulbecco’s modified Eagles’ medium 
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(DMEM, Corning Cellgro, Manassas, VA) supplemented with 10% fetal bovine 
serum (FBS, Atlanta biologicals, Flowery Branch, GA) and 1% penicillin-
streptomycin (Sigma) and incubated at 37oC in 5% CO2 balanced with humidified 
air for 24 h. In one well, 1 mL of 2 mg mL-1 of polymeric micelle solution (filtered 
by a 0.45 μm filter) was added. Serial dilutions were preformed to a final 
concentration of 0.25 mg mL-1. After incubation for 72 h, cell viability was 
assessed using MTT assay. 200 μL of sterile MTT solution (4 mg mL-1) was 
added into the culture wells and incubated for 4 h. The medium containing 
unreacted MTT was removed and 300 μL DMSO was added to dissolve the 
insoluble purple formazan crystals formed in cellular mitochondria. The 
absorbance at 590 nm was measured with a plate reader (BioTek) and results 
were recorded as viability percentage calculated against the control group without 
micellar challenge. All experiments were carried out in triplicate. 
4.4. RESULTS AND DISCUSSION 
4.4.1. Synthesis and characterization of amphiphilic prodrug polymers 
Figure 1 A-D describes the preparation of 5’DFUR-PCL-MPEG copolymer. First, 
5’DFUR-PCL was directly synthesized via the ring-???????????????????????????-
CL initiated by 5’DFUR as previously reported [21]. 1H NMR spectra of prodrug 
5’DFUR and 5’DFUR-PCL post synthesis are shown in Figure 4.2 (i) and (ii), 
respectively. Characteristic resonance peaks associated with 5’-DFUR including 
???????????-CH3), 4.20 (f-CH), 5.02 (e-CH), 5.25 (d-CH), 5.95 (c-CH), and 7.97 
(b-CH) ppm were seen in synthesized 5’-DFUR-PCL. Chemical shifts associated 
with PCL were seen at 1.40 (3- CH2), 1.65 (2-CH2), 2.34 (1-CH2), 3.62 (4’-CH2), 
and 4.05 (4-CH2) ppm.  These spectra demonstrated evidence of ring-opening 
??????????????? ??? ?-CL by prodrug 5’-DFUR. GPC data concerning the 
polymerization of PCL by 5’DFUR is given in Table 4.1, accordingly, the number 
average molecular weight (Mn) of 5’DFUR-PCL polymer was approximately 15 
kDa with a polydispersity index (PDI) of 1.24.  
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  Hydrophobic 5’DFUR-PCL was further grafted with MPEG (MW=5,000) as 
shown in Figure 4.1 B-D. GPC analysis revealed that 5’DFUR-PCL-MPEG 
amphiphilic copolymer had a Mn of 28 kDa and PDI of 1.19 (Table 4.1). Figure 
4.3 (iii) and (iv), shows the 1H NMR of MPEG-NH2 and 5’DFUR-PCL-MPEG. The 
peaks at 3.63 (A-OCH2) attributed to MPEG can be clearly seen in Figure 4.3 (iv). 
Due to the conjugation of MPEG to 5’DFUR-PCL through amide linkage (Scheme 
 
Figure 4.1. Synthetic scheme of (A) 5’DFUR-PCL, (B) 5’DFUR -PCL-COOH, (C) 
5’DFUR -PCL-NHS, and (D) 5’DFUR -PCL-MPEG. 
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4.1 D), the change of the peak at 1.79 (B-NH2) from a singlet in Figure 4.3 (iii) to 
a multiplet in Figure 4.3 (iv) further confirms conjugation of MPEG to hydrophobic 
5’DFUR-PCL. Further characterization of successful grafting of MPEG to 
hydrophobic 5’DFUR-PCL was examined through FTIR analysis. 
 
FTIR was employed to show the successful grafting of MPEG to 5’-DFUR-
PCL-NHS (Scheme 4.1 D). FTIR spectra of 5’DFUR-PCL (A), MPEG-NH2 (B) and 
5’DFUR-PCL-MPEG (C) are shown in Figure 4.4. C-H stretching vibrations can 
be seen from 2957-2839 cm-1 for all samples. Typical FTIR absorption peaks of 
PCL and MPEG at 1721 cm-1 attributed to the C=O stretching and at 1103 cm-1 
of the C-O-C, respectively, were seen in the FTIR spectra. These peaks, as well 
as characteristic peaks contributed from 5’-DFUR such as C-F stretching at 1049 
cm-1, C-N stretching of the primary and secondary aromatic amine at 1627 and 
1237 cm-1 were all found in Figure 4.4 (A) and (C). Showing successful initiation 
of polymerization of ?-CL by 5’DFUR. 
Figure 4.2. 1H NMR spectra of (i) 5’DFUR and (ii) 5’DFUR-PCL. 
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Figure 4.3. 1H NMR spectra of (iii) MPEG and (iv) 5’DFUR-PCL-MPEG. 
Figure 4.4. FTIR spectra of (A) 5’DFUR-PCL, (B) MPEG-NH2, and (C) 5’DFUR-PCL-
MPEG. 
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Table 4.1. Characterization of 5’DFUR-PCL-MPEG amphiphilic copolymera 
Sample Mw (Da) 
Mn 
(Da) 
Polydispersity 
(Mw/Mn) 
5’DFUR-PCL 18796 15158 1.24 
5’DFUR-PCL-MPEG 33927 28510 1.19 
MPEG350-PCL 24600 17053 1.44 
MPEG350-PCL-MPEG 19415 21624 1.36 
aMeasured by GPC 
4.4.2. Formation and characterization of 5’DFUR-tagged polymeric micelles 
It is known that amphiphilic polymers can self-assemble into micelles in selected 
solvent. The amphiphilic 5’DFUR-PCL-MPEG copolymer used in this study, could 
self-assemble into micelles in aqueous solution by the solvent-evaporation 
method. Here, despite 5’DFUR being slightly water soluble, 5’DFUR-PCL was 
the hydrophobic core segment and MPEG was the hydrophilic outside shell. In 
control micelles, MPEG350-PCL was the hydrophobic core segment and MPEG 
was the hydrophilic segment. The average size of 5’DFUR-tagged micelles and 
control micelles with and without encapsulating DOX or SN-38 and zeta potential 
as determined by dynamic light scattering (DLS) and zetasizer are shown in 
Table 4.2. The size of 5’DFUR-PCL-MPEG micelles was around 220.5 nm with a 
zeta potential of 1.2 mV due to the neutral change of MPEG (Figure 4.5 (A)). 
Micelles were also characterized by TEM analysis as shown in the Figure 4.5 
inset. The size of the micelles in the TEM images was slightly lower than the 
results from DLS with an average particle size of ~150 nm. This size fluctuation 
is due to the fact that DLS records the hydrodynamic radius of particles which is 
often times slightly larger than the actual particle size. As shown in Table 4.2, 
encapsulation of DOX or SN-38 did not affect the particle size substantially with 
an average size of 167.5 and 267.5 nm, respectively.  
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Table 4.2. Characteristics and drug loading of 5’DFUR-tagged polymeric micelles 
Sample Size (nm) 
Zeta 
(mV) 
Drug loading 
content
(%) 
Entrapment 
efficiency
(%) 
5’DFUR-PCL-MPEG 220.5 1.23 -- -- 
5’DFUR-PCL-MPEG 
(DOX) 167.5 -0.11 10.8 68.8 
5’DFUR-PCL-MPEG 
(SN-38) 267.5 1.01 3.4 86.3 
MPEG350-PCL-MPEG 202.5 0.74 -- -- 
MPEG350-PCL-MPEG 
(DOX) 222 2.15 10.4 65.6 
MPEG350-PCL-MPEG 
(SN-38) 148 1.21 3.9 97.6 
 
The CMC of 5’DFUR-PCL-MPEG was determined using pyrene as a 
hydrophobic florescent probe to confirm formation of micellear structures [28]. 
Figure 4.5 B shows the CMC value of 5’DFUR-tagged polymeric micelles in 
Figure 4.5. (A) Particle size distribution, and (B) plot of the intensity ratio (II/IIII) versus 
concentration of 5’DFUR-PCL-MPEG micelles. Inset represents TEM image. 
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aqueous medium. The intensity ratio of the first and third vibrational bands 
(I338/I335) against polymer concentration (Log(concentration)) in pyrene excitation 
spectra was plotted. A flat region in the low concentration extreme and sigmoidal 
region in the crossover region was found, and the CMC of 5’DFUR-tagged 
micelles was 56 mg L-1. 
4.4.3 Evaluation of drug loading content and entrapment efficiency 
Table 4.2 summarizes the drug loading content and entrapment efficiency of 
5’DFUR, DOX, and SN-38 in both 5’DFUR-tagged polymeric micelles and control 
micelles. To determine the drug loading percentage of 5’DFUR per mg of micelle 
formulation, the absorbance of 5’DFUR before and after drug release (t=0, t=72 
h) was examined and compared to a standard calibration curve of 5’DFUR. It was 
found that 5’DFUR comprised 9.8% of 5’DFUR-PCL-MPEG micelles. Due to the 
hydrophobic nature of SN-38, it was surmised that the extent of drug loading and 
entrapment would be high. As can be seen in Table 4.2, our results showed that 
the drug loading content and entrapment efficiency of SN-38 in 5’DFUR-PCL-
MPEG and control micelles was 3.4% and 86.3% and 3.9% and 97.6%, 
respectively. In contrast, DOX which is slightly hydrophilic had a lower 
encapsulation efficiency at 68.8% and 65.6% in prodrug-tagged polymeric 
micelles and control micelles, respectively. However, due to the fact that more 
DOX was used for encapsulation, the drug loading content was higher at 10.8% 
and 10.4% It is known that drug encapsulation efficiency is a crucial design 
parameter in the development of therapeutic nanocarriers. An ideal nano-carrier 
should have a high drug encapsulation efficiency and small size to evade the 
MPS. The synthesized 5’DFUR-tagged micelles developed here exhibit both of 
these qualities. 
4.4.4. In vitro drug release 
The in vitro release behavior of 5’DFUR both at 37oC with and without esterase 
was studied and the results are shown in Figure 4.6 A and B, respectively. To 
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mimic cellular conditions, esterase at a concentration of 3 units/2 mL was chosen 
[29]. A two-phase release profile was observed in all conditions with a burst 
release within the first 2 h followed by sustained release pattern up to 72 h. It was 
found that it required 2 h before esterase was able to increase the release of 
5’DFUR. This observation is in line with other researchers due to the fact that 
esterase has to take time to diffuse into the micelle and to activate [30, 31]. The 
release of 5’DFUR in samples without esterase was caused by hydrolysis of ester 
linkage between 5’DFUR and PCL. It is surmised that the sustained release of 
5’DFUR compared to previously reported prodrug release is due to that fact that 
polymerization can be initiated at two hydroxyl points [32]. Accumulative release 
of each sample reached a maximum between 78-86%.  
 The release of 5’DFUR from 5’DFUR-PCL-MPEG was modeled using both 
Power Law and Langmuir models as shown in Figure 4.6 A and B. The Power 
Law model was not a good fit for the release of 5’DFUR from polymeric micelles. 
Here, we obtained an exponent, n, value equal to 0.24 and 0.30 with and without 
esterase, respectively. If n is 0.43, for a sphere, this would indicate Fickian 
diffusion [33]. Due to the fact that our release is not solely though diffusion (i.e. 
5’DFUR is chemically bound to PCL though ester bond), our release is reaction 
 
Figure 4.6. In vitro drug release profile of 5’DFUR from 5’DFUR-PCL-MPEG micelles 
in PBS at 37oC (A) with esterase, (B) without esterase (mean ± SD, n = 3). 
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diffusion. Here, the prodrug 5’DFUR, is released through hydrolysis (Figure 4.6 
B) or a combination of hydrolysis and esterase (Figure 4.6 A). Therefore, we 
chose to also model our data with the Langmuir model. The Langmuir model is 
an enzyme kinetics model, and as can be seen in Figure 4.6, a good fit for the 
release of 5’DFUR from polymeric micelles. The dissociation constant (Kd) for the 
release of 5’DFUR from 5’DFUR-PCL-MPEG was found to be 1.48 and 3.07 with 
and without esterase, respectively. Similar to the release of GCV in Chapter 3, 
our K value was higher when esterase was not added showing that the 
association of 5’DFUR to PCL is stronger than ACV (Chapter 2). We speculate 
that this stronger association is due to the fact that 5’DFUR, like GCV, has two 
reactive points to initiate polymerization of ?-CL.  
The release of DOX and SN-38 at 37oC in 5’DFUR-PCL-MPEG is shown 
in Figure 4.7. The release profiles showed that a cumulative release of DOX and 
SN-38 from 5’DFUR-tagged micelles in PBS at 37oC was 87% and 62%, 
respectively, after 48 h. Moreover, we modeled the data using the Power Law 
 
Figure 4.7. In vitro drug release profiles of DOX and SN-38 from 5’DFUR-PCL-
MPEG micelles in PBS at 37oC (mean ± SD, n = 3). 
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and it was found to be a good fit for both of the encapsulated chemotherapeutic 
drugs. For the release of DOX and SN-38, we obtained n values of 0.41 and 0.43. 
These values are very close to the exponent value n (0.43) for the Fickian 
diffusion of a sphere. Indicating that Fickian diffusion is most likely the release 
mechanism for encapsulated chemotherapy drugs DOX and SN-38. 
4.4.5. Cytotoxicity of 5’DFUR-tagged polymeric micelles loaded with 
chemotherapeutic agents 
In vitro toxicity of polymeric prodrug micelles to parental HT29 cells was 
evaluated. Due to the fact that HT29 cells express endogenous TP levels [34], 
5’DFUR released from micelles would be converted to its active and toxic form 5-
FU. Figure 4.8 compares the viability of control micelles and 5’DFUR-PCL-MPEG 
micelles. Here, it can be seen that micelles without prodrug are nontoxic up to a 
concentration of 2 mg mL-1 (Figure 4.8 A). In contrast, the viability of HT29 cells 
is decreased to 60% when challenged with 2 mg mL-1 5’DFUR-PCL-MPEG 
micelles for 72 h (Figure 4.8 B). Moreover, it is shown that a concentration of 
5’DFUR-tagged micelle greater than or equal to 0.5 mg mL-1 is needed for cell 
death to occur. For this reason subsequent cytotoxicity studies with 
chemotherapeutic drugs DOX and SN-38 were not evaluated below 0.5 mg mL-
1. 
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Figure 4.8. Cell viability of HT29 cells after treatment with polymeric micelles for 
24, 48, and 72 h. (A) MPEG-PCL-MPEG polymeric micelles, (B) 5’DFUR-PCL-
MPEG polymeric micelles.  
A 
B 
110 
As can be seen from Figure 4.9 and Figure 4.10, HT29 cell viability was 
decreased in both control (A) and prodrug-tagged micelles with encapsulated 
chemotherapy drug (B). Control micelles without chemotherapy drug, showed 
little to no toxicity (Figure 4.8 A), after the encapsulation of DOX or SN-38 into 
MPEG-PCL-MPEG micelles, viability was reduced to 53% and 43%, respectively, 
with the highest dose for 72 h (Figure 4.9 A and Figure 4.10 A). Toxicity of HT29 
cells treated with 5’DFUR-PCL-MPEG micelle with encapsulated DOX showed 
an increased cell death from 60% viability without DOX to 36.6% viability (Figure 
4.9 B). This corresponds to an additive effect from both 5’DFUR converted to 5-
FU by endogenous TP gene plasmid and DOX chemotherapy drug. The toxicity 
of 5’DFUR-tagged micelles which encapsulated SN-38 was also increased from 
60% cell viability to 31% again showing an additive effect between 5’DFUR and 
chemotherapy drug SN-38 in cancer cell treatment. The results of cell viability 
show that delivery of 5’DFUR-tagged polymeric micelles can decrease viability of 
HT29 cells and that encapsulation of chemotherapy drugs can substantially 
increase cell death. 
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 Figure 4.9. Cell viability of HT29 cells after treatment with polymeric micelles 
encapsulating DOX for 24, 48, and 72 h. (A) MPEG-PCL-MPEG polymeric 
micelles, (B) 5’DFUR-PCL-MPEG polymeric micelles. 
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Figure 4.10. Cell viability of HT29 cells after treatment with polymeric micelles 
encapsulating SN-38 for 24, 48, and 72 h. (A) MPEG-PCL-MPEG polymeric 
micelles, (B) 5’DFUR-PCL-MPEG polymeric micelles. 
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4.5. CONCLUSION 
The results of this study show that 5’DFUR-PCL-MPEG micelles were 
synthesized and characterized. Moreover, results showed that polymeric micelles 
of 5’DFUR-PCL-MPEG successfully delivered prodrug into HT29 colon cancer 
cells and it was clearly revealed that endogenous TP in parental HT29 colon 
cancer cells could convert prodrug 5’DFUR into cytotoxic 5-FU thereby killing the 
cells. Moreover, co-delivery of 5’DFUR and DOX or SN-38 greatly enhanced the 
cell death. Development of similar prodrug nanocarrier show potential for 
enhancing the effectiveness of gene-directed enzyme prodrug therapy. 
 
  
   
114 
4.6. REFERENCES 
1. De Gramont A, Louvet C, André T et al. A review of GERCOD trials of bimonthly 
leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal 
cancer: evolution of a Regimen. European Journal of Cancer 34(5), 619-626 
(1998). 
2. Shimma N, Umeda I, Arasaki M et al. The design and synthesis of a new tumor-
selective fluoropyrimidine carbamate, Capecitabine. Bioorganic and Medicinal 
Chemistry 8(7), 1697-1706 (2000). 
3. Bronckaers A, Gago F, Balzarini J et al. The dual role of thymidine phosphorylase 
in cancer development and chemotherapy. Medicinal Research Reviews 29(6), 
903-953 (2009). 
4. Patterson AV, Zhang H, Moghaddam A et al. Increased sensitivity to the prodrug 
5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in 
MCF-7 cells transfected with thymidine phosphorylase. British Journal of Cancer 
72(3), 669-675 (1995). 
5. Haraguchi M, Furukawa T, Sumizawa T et al. Sensitivity of human KB cells 
expressing platelet-derived endothelial cell growth factor to pyrimidine 
antimetabolites. Cancer Research 53(23), 5680-5682 (1993). 
6. Nakano Y, Ohota J, Fujita M et al. Clinical effect of 5'-deoxy-5-fluorouridine (5'-
DFUR). Gan No Rinsho 31(6 Suppl), 746-750 (1985). 
7. Sumimoto R, Takahashi M, Etoh T et al. Effectiveness of high-dose, intermittent 
5'-DFUR therapy for advanced gastric cancer. Gan To Kagaku Ryoho 28(1), 83-
86 (2001). 
8. Hirano M, Kato A, Murakami N et al. A case of recurrent colon cancer treated 
markedly effective with 5'-DFUR. Gan To Kagaku Ryoho 20(8), 1063-1066 
(1993). 
9. Tagaya N, Kakihara Y, Hamada K et al. Docetaxel (TXT), epirubicin (EPI) and 
doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients 
with locally advanced breast cancer. Gan To Kagaku Ryoho 31(13), 2155-2158 
(2004). 
10. Iba T, Kidokoro A, Fukunaga M et al. The efficacy of combination chemotherapy 
of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and 
medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer 
patients. Gan To Kagaku Ryoho 28(7), 973-977 (2001). 
11. Takatsuka Y, Yayoi E, Miyauchi K et al. A comparative study with 5'-DFUR alone 
or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) 
for advanced or recurrent breast cancer. Gan To Kagaku Ryoho 19(5), 631-636 
(1992). 
12. Pierri E, Avgoustakis K. Poly(lactide)-poly(ethylene glycol) micelles as a carrier 
for griseofulvin. Journal of Biomedical Materials Research Part A 75A(3), 639-
647 (2005). 
13. Yue J, Liu S, Wang R et al. Transferrin-conjugated micelles: Enhanced 
accumulation and antitumor effect for transferrin-receptor-overexpressing cancer 
models. Molecular Pharmaceutics 9(7), 1919-1931 (2012). 
14. Tabatabaei Rezaei SJ, Nabid MR, Niknejad H et al. Multifunctional and 
thermoresponsive unimolecular micelles for tumor-targeted delivery and site-
specifically release of anticancer drugs. Polymer 53(16), 3485-3497 (2012). 
15. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-
incorporating polymer micelles. Cancer Science 100(4), 572-579 (2009). 
115 
16. Hamaguchi T, Kato K, Yasui H et al. A phase I and pharmacokinetic study of 
NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Britsh 
Journal of Cancer 97(2), 170-176 (2007). 
17. Matsumura Y, Hamaguchi T, Ura T et al. Phase I clinical trial and 
pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. 
British Journal of Cancer 91(10), 1775-1781 (2004). 
18. Chabner BA, Longo DL. Cancer chemotherapy and biotherapy: Principles and 
practice.  Lippincott Williams & Wilkins, (2011). 
19. Slatter JG, Schaaf LJ, Sams JP et al. Pharmacokinetics, metabolism, and 
excretion of irinotecan (CPT-11) following iv infusion of [14C] CPT-11 in cancer 
patients. Drug Metabolism and Disposition 28(4), 423-433 (2000). 
20. Rothenberg ML, Kuhn JG, Burris H et al. Phase I and pharmacokinetic trial of 
weekly CPT-11. Journal of Clinical Oncology 11(11), 2194-2204 (1993). 
21. Chang KY, Lee YD. Ring-???????????????????????????-caprolactone initiated by 
the antitumor agent doxifluridine. Acta Biomaterialia 5(4), 1075-1081 (2009). 
22. Albertsson A-C, Varma IK. Recent Developments in Ring Opening 
Polymerization of Lactones for Biomedical Applications. Biomacromolecules 
4(6), 1466-1486 (2003). 
23. Cerrai P, Tricoli M. Block copolymers from L-lactide and poly(ethylene glycol) 
through a non-catalyzed route. Die Makromolekulare Chemie, Rapid 
Communications 14(9), 529-538 (1993). 
24. Zhang Y, Li X, Zhou Y et al. Preparation and Evaluation of Poly(Ethylene Glycol)-
Poly(Lactide) Micelles as Nanocarriers for Oral Delivery of Cyclosporine A. 
Nanoscale Research Letters 5(6), 917 - 925 (2010). 
25. Xue B, Wang Y, Tang X et al. Biodegradable self-assembled MPEG-PCL 
micelles for hydrophobic oridonin delivery in vitro. Journal of Biomedicine and 
Nanotechnology 8(1), 80-89 (2012). 
26. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer 
therapy. Advanced Drug Delivery Reviews 56(11), 1649-1659 (2012). 
27. Wilhelm M, Zhao CL, Wang Y et al. Poly(styrene-ethylene oxide) block copolymer 
micelle formation in water: a fluorescence probe study. Macromolecules 24(5), 
1033-1040 (1991). 
28. Kalyanasundaram K, Thomas JK. Environmental effects on vibronic band 
intensities in pyrene monomer fluorescence and their application in studies of 
micellar systems. Journal of the American Chemical Society 99(7), 2039-2044 
(1977). 
29. Liewald F, Demmel N, Wirsching R et al. Intracellular pH, esterase activity, and 
DNA measurements of human lung carcinomas by flow cytometry. Cytometry 
11(3), 341-348 (1990). 
30. Fukuda M, Kunugi S. Kinetic studies of wheat carboxypeptidase-catalyzed 
reaction: Differences in pressure and temperature dependence of peptidase and 
esterase activities. Journal of Biochemistry 101(1), 233-240 (1987). 
31. Guichard S, Terret C, Hennebelle I et al. CPT-11 converting carboxylesterase 
and topoisomerase activities in tumour and normal colon and liver tissues. British 
Journal of Cancer 80(3-4), 364-370 (1999). 
32. Sawdon AJ, Peng CA. Polymeric micelles for acyclovir drug delivery. Colloids 
and Surfaces B: Biointerfaces 122(1), 738-745 (2014). 
33. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. International 
Journal of Pharmaceutics 364(2), 328-343 (2008). 
116 
34. Schwartz EL, Baptiste N, Wadler S et al. Thymidine phosphorylase mediates the 
sensitivity of human colon carcinoma cells to 5-fluorouracil. Journal of Biological 
Chemistry 270(32), 19073-19077 (1995). 
 
117 
 
CHAPTER 5: DEVELOPMENT OF ANTIPHAGOCYTIC CD47-
?????????????????????????????????????v?3 INTEGRIN-
BEARING TUMOR CELLS5 
5.1. ABSTRACT 
Methoxy(polyethylene glyocol) (MPEG) was used as the initiator in ring-opening 
???????????????????-caprolactone to form hydrophobic MPEG-polycaprolactone, 
which was then grafted to hydrophilic cationic polymeric polyethyleneimine to 
form amphiphilic copolymers for the preparation of stable micellar nanoparticles. 
The formed polymeric micelles were biotinylated via the interaction of biotin/EDC 
with the amines on cationic polymers. CD47-streptavidin (extracellular domain of 
self-marker CD47) fusion protein was expressed in BL21(DE3) bacteria and then 
the crude protein used directly. Through biotin-streptavidin affinity, CD47 was 
bound to biotinylated polymeric prodrug micelles and showed antiphagocytic 
efficacy when CD47-tagged polymeric micelles were exposed to J774A.1 
macrophages. Since CD47 is not only an antiphagocytic ligand but also an 
????????????????????????????? ????????????????????????????? ??????????v?3, which is 
overexpressed on tumor-activated neovascular endothelial cells. In this study, 
CD47-tagged polymeric prodrug micelles were employed to treat two cells lines 
-?????????????????????????v?3 ??????????????????????????v?3 expression. Results 
show that functionalized polymeric micelle drug carriers were successfully 
??????????????????????v?3 by using CD47 as a targeting moiety.  
5.2. INTRODUCTION 
Drug delivery carriers have the potential not only to treat but also diagnose many 
diseases. However, they still lack in complexity of natural particulates. Red blood 
cells, for example, exhibit all of the traits researchers want for their carriers: they 
possess a small size, flexibility and ability to evade the immune system for up to 
5The material contained in this chapter is planned for publication in ACS Biomaterials. 
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4 months [1]. In 2000, Oldenborg et al., reported that CD47 functioned as a 
marker of self on red blood cells [2]. It was found that as a red blood cell ages, 
CD47 expression levels do indeed decrease [3]. Moreover, it has been shown 
that CD47-streptavidin (CD47-SA) fusion protein endowed antiphagocytic effect 
to perfluorocarbon-based oxygen carriers [4]. Furthermore, since CD47 is an 
integrin associated protein [5]????? ?????????????????????????????????????v?3, which 
is overexpressed on tumor-activated neovascular endothelial cells and 
unexpressed on mature quiescent ones lined in blood vessels [6]. In this study, 
CD47-SA was bound on to biotinylated micelle carriers and the antiphagocytic 
?????????????????????????????????????????v?3 integrin examined.  
To this end, polymeric micelles were chosen as a model system for this 
study. Here, methoxy(poly ethylene glycol) (MPEG) possessing a hydroxyl group 
was used as the initiator of ?-caprolactone to obtain MPEG-??????-caprolactone) 
(MPEG-PCL). PCL, is widely used as a core-forming hydrophobic segment 
because of its biodegradablility and biocompatibility [7-9]. To form amphiphilic 
block copolymers for micelle preparation, hydrophilic polyethylenimine (PEI) was 
grafted onto hydrophobic MPEG-PCL. PEI is widely used for nonviral gene 
delivery [10-12]. Our results show that CD47-tagged polymer micelles can evade 
phagocytosis for up to 6 h. Moreover, carriers targeted to cells bearing high levels 
?????????????v?3 had much higher uptake of micelles after 4 h of treatment.   
5.3. MATERIALS AND METHODS 
5.3.1. Materials 
N,N’-????????????? ???????? ???? ??????? ?-CL, pyrene, and succinic anhydride 
were purchased from Acros Organics (Geel, Belgium). Sn(Oct)2, CDCl3 with 1% 
tetramethylsilane (TMS), deuterated dimethyl sulfoxide (DMSO-d6), dimethyl 
sulfoxide (DMSO), tetrahydrofuran (THF), dichloromethane (DCM), methanol, 2-
propanol, hexane, toluene, MPEG (MW = 350), PEI (MW = 10K), Biotin, and 1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) were all purchased from 
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Sigma-Aldrich (St. Louis, MO). Ethyl ether was purchased from J.T. Baker 
(Austin, TX). N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar (Ward 
Hill, MA). Acetone was purchased from Pharmco-AAPER (Shelbyville, KY). 
Pyridine and hydrochloric acid (HCl) were purchased from EMD (Philadelphia, 
PA). Sodium chloride (NaCl) and magnesium sulfate were purchased from 
Showa (Tokyo, Japan). All reagents were used as received without further 
purification. 
5.3.2. Synthesis of MPEG-PCL-PEI 
MPEG ????????????????????????????????????-CL (2.25 mL) under a sonication 
bath for 5 min at room temperature. Sn(Oct)2 ??????? ?????-CL) was then added 
into the mixture. The entire solution was placed into a 3-necked round-bottom 
flask. The system was purged with nitrogen and immersed in an oil bath at 140oC 
for 24 h. The crude product was cooled to room temperature, dissolved in DCM, 
and precipitated by cold methanol. The product was then vacuum dried by a 
rotary evaporator at 40oC. 
MPEG-PCL (0.5 mmol) and succinic anhydride (1 mmol) were weighed 
and dissolved in toluene in a 3-necked round-bottom flask. One mmol pyridine 
was added and the solution was reacted under nitrogen at 70oC for 48 h. The 
product was then precipitated by cold hexane, and spun down. The pellet was re-
dissolved in DCM and washed twice each with 10% (v/v) HCl and saturated NaCl 
solution. The organic phase was isolated and dried with magnesium sulfate then 
filtered. The carboxylated MPEG-PCL was recovered by precipitation in cold 
hexane and then vacuum dried by rotary evaporation at 40oC. 
MPEG-PCL-COOH (0.54 mmol) and NHS (2.7 mmol) were weighed and 
mixed in 15 mL DCM, and then DCC (2.7 mmol) was added. The reaction was 
run under a nitrogen environment at room temperature for 24 h. The precipitated 
byproduct 1,3-dicyclohexylurea was removed by vacuum filtration. The filtrate 
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was added into 35 mL diethyl ether and cooled to 4oC for 4 h to precipitate MPEG-
PCL-NHS. The precipitate was collected by centrifugation at 3,500 rpm for 5 min, 
washed with 2-propanol and solvent removed by rotary evaporation at 40oC. 
MPEG-PCL-NHS (10 mg) and PEI (MW = 10K) (10 mg) were weighed and 
dissolved by 20 mL DCM in a round-bottom flask. The flask was purged with 
nitrogen and the solution was stirred for 24 h. The solution was then dialyzed 
(MWCO = 6-8 kD, Spectra/Por, Rancho Dominguez, CA) against pure DCM to 
remove remaining PEI. MPEG-PCL-PEI was recovered by rotary evaporation at 
40oC. 
5.3.3. Preparation of polymeric micelles 
MPEG-PCL-PEI were formed by adding 10 mg of MPEG-PCL-PEI amphiphilic 
polymer, to 2 mL acetone and dissolving under bath sonication. The solution was 
then added dropwise to 10 mL deionized water under bath sonication. Acetone 
was removed by rotary evaporation and the final solution was collected by filtering 
through a 0.45 μm filter. 
5.3.4. Size and zeta potential measurements 
The average particle size of polymeric prodrug micelles was determined by a 
dynamic light scattering (DLS) instrument (Zetasizer Nano ZS, Malvern 
Instruments, United Kingdom) equipped with a red laser at a wavelength of 633 
nm and scattering angle of 90o at 25oC. The zeta potential of the micelles 
dispersed in deionized water was determined with a zeta potential analyzer 
(Zetasizer Nano ZS). 
5.3.5. Biotinylation of polymeric micelles 
EDC was used to activate biotin for subsequent reaction with polymeric micelles. 
Here, 1 mg Biotin and 1 mg EDC were dissolved in PBS for 15 min. Biotin/EDC 
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mixture was then added to MPEG-PCL-PEI micelles (1 mg mL-1) and mixed. After 
30 min, 10 μL FITC (5 mg mL-1 in DMSO) was added to the micelle/biotin/EDC 
mixture. After 3 h, the biotinylated micelles were purified by dialysis (MWCO = 6-
8 kD, Spectra/Por, Rancho Dominguez, CA) to remove excess biotin/EDC and 
FITC. 
5.3.6. Amplification and expression of CD47-SA fusion protein 
Mouse CD47 cDNA clone pME18S-FL3 CD47 was obtained from Dr. Stanley 
Tahara at University of Southern California. The extracellular domain of CD47 
was amplified from full-length mouse CD47 cDNA by polymerase chain reaction 
(PCR) with the sense primer 5’-GGCTCATGACAGCTCAACTACTGTTTAGT-3’ 
and the antisense primer 5’-GCGGGATCCTTTTCATTTGGAG-3’. The core 
streptavidin coding region was amplified by PCR from pSTE2-215 (yol), which is 
single chain antibody fused to core streptavidin, using PCR primers 5’-
CGGATCCTGGTGCTGCTGAAGCAGGTATCACCT-3’ and 5’-
GCTCGAGGGAGGCGGCGGACGG-3’. Core streptavidin was inserted between 
BamHI and XhoI site of pET20b (Novagen) to give pMA005. The extracellular 
domain of CD47 PCR product was inserted between the NcoI and BamHI site of 
pMA005 to yield pMA006. 
DH5????????????????? (Invitrogen) were used for plasmid amplification of 
pMA006. Briefly, 2 μL of plasmid solution was mixed with 100 μL competent cells. 
After incubating on ice for 30 min cells were heat-shocked for 45 sec in a 42oC 
water bath. Cells were added to 0.9 mL SOC medium and agitated in a shaker 
incubator at 37oC for 1 h. Cell suspension was added to agar plated containing 
50 μg mL-1 ampicillin and grown overnight. For CD47-SA expression, BL21(DE3) 
cells (Invitrogen) were used. Here, 5 μL pMA006 was added to 100 μL BL21(DE3) 
cells, incubated on ice for 30 min and then heat-shocked for 30 sec in a 42oC 
water bath. The cells were added to 0.250 mL SOC medium and then agitated in 
a shaker incubator at 37oC for 1 h. Cells were then spread on agar plates 
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containing 100 μg mL-1 ampicillin and incubated overnight at 37oC. One colony 
was chosen from the plate and grown until they reached mid-log (OD = 0.4). For 
induction, 1 mM isopropylthioglaactoside (IPTG) was added. Protein was purified 
from bacterial lysated by standard methods and then used directly for subsequent 
studies. 
5.3.7. Quantification of CD47-SA binding 
The amount of biotin conjugated onto the micelle surface was determined through 
the spectrophotometric method proposed by Green et al [13]. The basis of this 
assay is that the dye HABA binds to avidin, but is stoichiometrically displaced by 
biotin. Briefly, 10 mL DI water was added to HABA/avidin reagent (Sigma). In a 
96-well plate, 90 μL HABA/avidin reagent and 10 μL sample was added. The 
absorbance at 500 nm was then read. Using the beer lambert law, the amount of 
biotin/micelle particle was determined: 
??????
??????? ????????? =
?????
??????? 
?????
??
??????? ?????????
??
     (1) 
???????? ??? ???? ??????????? ??? ???? ??????? ??? ???? ???? ?? ??? ???? ????????????? ???
extinction coefficient, l is the cell path length expressed in cm and C is the 
concentration of the sample expressed in molarity. The amount of biotin 
calculated was then assumed to directly relate to the amount of CD47-SA bound 
onto the particle surface. 
5.3.8. Macrophage studies 
Murine macrophage cell line J774A.1 (ATCC) was used for phagocytosis assays. 
Cells (106) were plated in 6-well plates with 2 mL Dulbecco’s modified Eagles’ 
medium (DMEM, Corning Cellgro, Manassas, VA) supplemented with 10% fetal 
bovine serum (FBS, Atlanta biologicals, Flowery Branch, GA) and 1% penicillin-
streptomycin (Sigma) and incubated at 37oC in 5% CO2 balanced with humidified 
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air for 24 h.. Macrophage cells were then treated with CD47-tagged polymeric 
micelles and biotinylated polymeric micelles. The cells were imaged under Leica 
DMI3000 B microscope equipped with a Leica DFC360 FX camera (Leica 
Microsytems, Wetzlar, Germany) at 2 h, 4 h and 6 h. After each time point, cells 
were washed with PBS and then trypan blue solution (2 mg mL-1) was added to 
quench outside fluorescence and imaged again. Cells were then used directly for 
flow cytometry analysis (BD Accuri C6). 
5.3.9. Integrin targeting 
PC3 cells (ATCC), which overexpress integrin ?v?3, and BHK21 cells, which have 
low integrin ?v?3 expression, were used for integrin targeting studies. Cells (106) 
were plated in 6-well plates with 2 mL Dulbecco’s modified Eagles’ medium 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin and 
incubated at 37oC in 5% CO2 balanced with humidified air for 24 h. Cells were 
then treated with CD47-tagged polymeric micelles and biotinylated polymeric 
micelles. After 2 h and 4 h, cells were washed and 2 mg mL-1 trypan blue solution 
was added to quench outside fluorescent. Cells were imaged by fluorescent 
microscopy (Leica). 
5.4. RESULTS AND DISCUSSION 
5.4.1. Characterization of polymeric micelles 
Figure 5.1 (A-D), shows the synthesis of MPEG-PCL-PEI copolymer. Size and 
zeta analysis of polymeric prodrug micelles can be seen in Figure 5.2. An average 
size of 153.2 nm and zeta potential of 43.4 mV was seen for MPEG-PCL-PEI 
micelles.  
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Figure 5.1. Synthetic scheme of (A) MPEG-PCL, (B) MPEG-PCL-COOH, (C) 
MPEG-PCL-NHS, and (D) MPEG-PCL-PEI 
 
Figure 5.2. Size and zeta analysis of MPEG-PCL-MPEG. 
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 After synthesis of the copolymer, and self-assembly into micellear 
nanoparticles, biotin was added through EDC crosslinking (Figure 5.3). Here, 
biotin was activated by EDC and then allowed to bind onto the micelle surface for 
30 min before the addition of FITC for fluorescence. Biotin on the surface of 
polymeric micelles was measured using the HABA/avidin assay. A solution of 
HABA/avidin shows absorbance a 500 nm as avidin is displaced by the biotin 
which is bound on the micelle surface, the absorbance at 500 nm will decrease. 
As seen in Figure 5.4 (A), as the amount of biotinylated micelle added to the 
assay was decreased (0.5 dilution), the absorbance at 500 nm decreased. In 
contrast, after binding CD47-SA to the biotinylated micelle, no absorbance 
change was observed (Figure 5.4 B). This tells us two things, first we have 
successful binding of CD47-SA to bintinylated micelles and second, that the 
CD47-SA amount is sufficient to bind to all of the biotin molecules on the micelle 
surface.  
Using the Beer Lambert law, we were able to quantify the amount of biotin 
and therefore CD47-SA bound onto the micelle surface. Using equation 1, we 
found that the amount of biotin/micelle particle was equal to 2.25 x 10-17 mol 
Biotin/ micelle particle. After multiplying by Avagadro’s number, we found that the 
concentration of biotin on the surface of the micelles was 1.4 x 107 biotin 
molecules/micelle particle. Despite the fact that biotin and streptavidin have four 
 
Figure 5.3. Synthetic scheme of biotinylation and fluorescence of micelles. 
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potential binding sites, CD47-SA at 26 kDa is much larger than one biotin 
molecule. Therefore because of steric hindrance we believe that for every one 
biotin molecule on the micelle surface, one molecule of CD47-SA will bind.
Therefore, the amount of biotin molecules on the micelle surface will be equal to 
the amount of CD47-SA bound on the micelle surface. 
5.4.2. Antiphagocytic effect 
To observe the antiphagocytic effect endowed onto micelle particles by CD47-
SA, cell studies were conducted. As shown if Figure 5.5, cells treated readily
phagocytized biotinylated micelle particles while CD47-tagged particles showed 
little uptake. While little difference was seen after 2 h of treatment (most likely 
due to the small size of micelle particles) (Figure 5.5 A and B), 4 h and 6 h clearly 
show more fluorescence in biotinylated micelles (Figure 5.5 C and E) than in 
CD47-tagged micelles (Figure 5.5 D and F). 
The 6 h sample, which by fluorescent imaging showed the biggest 
difference in particle uptake by macrophages was run on flow cytometry. As can 
be seen from Figure 5.6, a shift in the mean fluorescent intensity of biotinylated 
and CD47-tagged micelles was seen. The mean fluorescence intensity of 
 
Figure 5.4. HABA/avidin assay. If biotin is present, HABA will be displaced from 
avidin resulting in a decrease of absorbance at 500 nm. (A) biotinylated micelles, and 
(B) CD47-tagged micelles. 
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biotinylated and CD47-tagged micelles was quite different at 3628.33 and 
2325.60, respectively. 
 
 
Figure 5.6. Flow cytometry analysis of J774A.1 macrophages after treatment with 
biotinylated and CD47-tagged micelles for 6 h. 
 
Figure 5.5. Effect of CD47 on micelle uptake by J774A.1 cells. (A) 2 h treatment with 
biotinylated micelles, (B) 2 h treatment with CD47-tagged polymeric micelles, (C) 4 h 
treatment with biotinylated micelles, (D) 4 h treatment with CD47-tagged polymeric 
micelles, (E) 6 h treatment with biotinylated micelles, and (F) 6 h treatment with 
CD47-tagged polymeric micelles.
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5.4.3. Integrin targeting 
Since CD47 is an integrin associated protein [5], it might be employed to target 
??????????v?3, which is overexpressed on tumor-activated neovascular endothelial 
cells and under expressed on mature quiescent ones lined in blood vessels [6]. 
In the previous section, we have shown that CD47 serves as an antiphagocytic 
ligand, to show that CD47 can also be used to target drug carriers, PC3 cells 
which show high levels of integ?????v?3 were treated with our CD47-tagged micelle 
carriers. As can be seen in Figure 5.7?? ?????? ????? ???? ?v?3 expression (BHK)
despite having micelle carriers surrounding the cells (Figure 5.7 A and B) showed 
very little uptake of micelle carriers after trypan blue treatment (Figure 5.7 C and 
D). In contrast, PC3 cells showed a much higher uptake level of micelle carriers 
after trypan blue treatment (Figure 5.8 C and D). 
 
 
Figure 5.7. Integrin targeting to BHK21 ????????????????????????????????????v?3 
integrin. BHK21 cells were treated with CD47-tagged micelle carriers for 4 h. (A) 
Fluorescent image, (B) overlay of bright field and fluorescent image, (C) 
fluorescent image after trypan blue treatment to quench outside fluorescent, and 
(D) overlay of bright field and fluorescent image. 
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 5.5. CONCLUSIONS 
In this study, biotinylated polymeric micelles were successfully synthesized. 
Moreover, CD47-SA was conjugated onto the micelle surface via biotin/SA 
affinity. Macrophages treated with CD47-tagged micelles revealed and 
increased antiphagocytic effect as well as increased the uptake into cells with 
??????v?3 expression.  These results indicated that CD47 can be utilized not 
only as an antiphagocytic ligand but also serve to target drug carriers onto 
abnormal e?????????????????????????????????????????v?3 and thereby block tumor 
angiogenesis. CD47-tagged nanocarriers could potentially be developed 
enhanced anticancer therapy due to their immune evasion and targeting 
capabilities.  
 
Figure 5.8. Integrin targeting to PC3 cells which have high ???????????????v?3 
integrin. PC3 cells were treated with CD47-tagged micelle carriers for 4 h. (A) 
Fluorescent image, (B) overlay of bright field and fluorescent image, (C) 
fluorescent image after trypan blue treatment to quench outside fluorescent, and 
(D) overlay of bright field and fluorescent image. 
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CHAPTER 6:  SUMMARY AND FUTURE DIRECTIONS 
6.1. THESIS CONCLUSIONS AND SUMMARY OF FINDINGS 
Gene-directed enzyme prodrug therapy is a promising approach. Some major 
problems remain to be solved before enzyme/prodrug strategies can become a 
routine therapeutic approach, largely due to inefficient drug/gene delivery. The 
findings in this thesis outlines an innovative approach for delivery of prodrug, 
gene and cytotoxic drug to malignant cells.   
 Prodrugs acyclovir (ACV), ganciclovir (GCV), and 5-doxifluridine (5’DFUR) 
were used as the sole initiators in the poly???????????????-???????????????-CL). 
The prodrug-tagged poly(caprolactone) PCL was then grafted with hydrophilic 
polymers for form amphiphilic block copolymers. Synthesis of prodrug-tagged 
polymeric micelles was followed via standard analytical means including 1H NMR, 
FTIR, GCP, size and zeta analysis, and CMC. Our results indicate that prodrug-
tagged micelles between 100-200 nm can be synthesized. Studies with ACV 
confirmed bioavailability of prodrug-tagged polymeric micelles up to a 
concentration of 500 mg mL-1. Cytotoxity studies with GCV confirmed that a one-
step GDEPT process is a feasible anticancer therapy approach. It was found that 
4.5 μg of HSV-TK gene plasmid complexed onto GCV-PCL-chitosan micelles 
was sufficient to decrease cell viability to 52%. This was a 25% increase in cell 
death compared to the conventional two-step delivery of gene, followed by 
prodrug. Cytotoxicity studies with 5’DFUR, confirmed that suicide gene/prodrug 
pairs, in conjunction with treatment from other chemotherapy drugs, can 
substantially increase cell toxicity.  
 Furthermore, in an effort to develop multifunctional polymeric micelle 
carriers which can evade the immune system and target to tumor cells, CD47-SA 
was tagged onto the micelle surface via biotin/SA affinity. Our studies indicate 
that CD47-tagged micelle carrier can evade macrophage phagocytosis for up to 
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?????????????????????????????????????????????????????????????????????v?3, micelle 
uptake was increased considerably. 
6.2. FUTURE DIRECTIONS 
This thesis has shown the feasibility of polymeric micelle carriers for the 
delivery of prodrug/gene and prodrug/cytotoxic drugs to tumor cells. Further work 
can be conducted to deliver all three (prodrug, gene and cytotoxic drug) 
simultaneously to malignant cells. Based on the results established here, 
anticancer therapy would be enhanced by a GDEPT system optimized for one-
step delivery.  
Moreover, this thesis has shown that extracellular targeting and 
antiphagocytosis can be achieved by binding CD47-SA onto the micellar surface. 
It would be of interest, especially in the case of one-step delivery, to use a nuclear 
localization sequence (NLS) to target the micelle carrier or DNA to the nucleus. 
A NLS is an amino acid sequence that tags a protein for import into the cell 
nucleus by nuclear transport [1]. For our proposed one-step delivery method, the 
DNA bound onto chitosan is delivered through passive diffusion. The application 
of NLS peptides for nonviral gene transfer has been widely investigated [2-4]. 
Therefore, the addition of an NLS onto the DNA or micelle carrier would allow for 
active targeting which should enhance gene efficiency greatly.  
The work conduced in this thesis also has the potential to be applied to 
other GDEPT systems, including but not limited to, cytosine deaminase (CD)/5-
fluorocytosine (5-FC). 5-FC is one of the main anticancer drugs used to treat 
colon, pancreatic and breast cancers. Similar to 5’DFUR, 5-FC is converted to 5-
FU by CD. CD, unlike TP, has little cellular activity in humans and therefore 
increasing tumor cell proliferation is not a fear. Moreover, CD/5-FC has one of 
the strongest bystander effects demonstrated [5] and has shown more effective 
than the HSV-TK/GCV system in the treatment of renal and colorectal cancers 
[6, 7]. In addition to enhanced anticancer effectiveness, ring-opening 
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???????????????????–CL by 5-FC would be initiated by an amine group, rather than 
a hydroxyl group as shown in the currently discussed prodrugs. Amine initiation 
has several advantages because the prodrug will not be cleaved as easily from 
the micelle carrier therefore allowing for extended release of the drug (see Figure 
6.1) and increased activation time of the gene in a one-step delivery system. 
Oledzka et al. previously showed that amino acids can be used as initiators ????–
CL and L,L-lactide polymerization [8]. Therefore, it is reasonable that 5-FC can 
be used to created prodrug-tagged polymeric micelles. Based on the drug release 
profile for 5-FC, it can be seen that compared to the previously used 
gene/prodrug pairs discussed in this thesis, the release profile of 5-FC is 
extensively enhanced. Here, it takes up to 12 h before 50% of the prodrug is 
released. Moreover, if we model the release data using the Langmuir model, we 
get a dissociation constant (Kd) of 7.77, this shows a much stronger association 
then any of the previously discussed gene/prodrug pairs. 
   
 
Figure 6.1. In vitro drug release profile of 5-FC from 5-FC-PCL-MPEG in PBS at 
37oC. 
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